handbook · ian wicks australia heather wisbey australia peter wong australia daniel wright new...

HANDBOOK

#APLAR19 aplar2019.com

http://www.aplar2019.com

ARAAPLARPre-congress

workshops

Scientific Program Speakers Abstracts

Industry Program Exhibitors Sponsors

The APLAR-ARA 2019 scientific program is subject to change and this is correct at the time of creation.

Welcome to APLAR-ARA 2019 02

Executive Committee 03

APLAR Committees 03

Local Organising Committee 03

Faculty Listing 04

About Brisbane 05

Download the Congress App 06

Congress Venue 07

General Information 08

Social Functions & Ceremonies 11

Pre-Congress Workshops & Courses 13

Industry Program 14

Congress Program 17

Poster Presentations 22

Lilly USB & Abstract Journal 31

Exhibition 32

Sponsor Profiles 33

Acknowledgements 36

Join the conversation

Facebook “f ” Logo CMYK / .eps Facebook “f ” Logo CMYK / .eps

01APLAR-ARA 2019 HANDBOOK#APLAR19 Back to contents

CONTENTS

#APLAR19

https://twitter.com/APLAR_org

https://www.facebook.com/APLAR.org/

https://www.linkedin.com/company/aplar/

The 21st Asia Pacific League of Associations for Rheumatology Congress, co-hosted by the Australian Rheumatology Association will be held from 8-11 April in Brisbane, Australia. APLAR-ARA 2019 will provide a forum for exchange on cutting edge scientific and clinical information. The congress will draw on international, regional and Australasian speakers to provide world-class research, scientific and medical content for our attendees.

The congress will facilitate interactions among physicians, researchers, scientists, clinicians and other health professionals from the Asia Pacific region, and around the world. With APLAR member national societies now representing 25,000+ rheumatologists in the APAC region, we are working to ensure that APLAR-ARA 2019 Brisbane is a high-impact congress, providing representative exposure to APLAR’s many member societies, and a lasting legacy for rheumatology both in Australia and the Asia-Pacific region.

The APLAR-ARA 2019 Congress theme will be reflected through the scientific program in a series of high-profile plenary presentations, concurrent sessions, pre-congress workshops and poster presentations. Our industry partners continue to play a role in thought leadership through curation of content in the industry program, and also support for the continuing medical education of Rheumatologists in our region.

We look forward to welcoming you to Brisbane.

Prof Syed Atiqul HaqAPLAR PresidentProfessor of Rheumatology,BSM Medical University, Dhaka, Bangladesh

Prof Matt BrownAPLAR-ARA 2019 Congress ChairDirector of Genomics,Queensland University of Technology, Brisbane, Australia

TO THE 21ST ASIA PACIFIC LEAGUE OF ASSOCIATIONS FOR RHEUMATOLOGY CONGRESS 2019


PresidentSyed Atiqul Haq, Bangladesh

President ElectDebashish Danda, India

Vice PresidentsYeong-Wook Song, South KoreaZeng Xiaofeng, China

Secretary GeneralChi-Chen Chang, Taiwan

Deputy Secretary GeneralNazrul Islam, Bangladesh

TreasurerJose Paulo Lorenzo, Philippines

Singapore DirectorYew Kuang Cheng, Singapore

Immediate Past PresidentKazuhiko Yamamoto, Japan

EXECUTIVE COMMITTEE

APLAR COMMITTEES

LOCAL ORGANISING COMMITTEE

Scientific CommitteeChairsYoshiya Tanaka, JapanRohini Handa, India

Education CommitteeChairWorawit Louthrenoo, Thailand

Standing CommitteesCOPCORD CoordinatorArvind Chopra, India

International Affairs CommitteeChairsLai-Shan Tam, ChinaZhanguo Li, China

MembersYeong-Wook Song, KoreaWorawit Louthrenoo, ThailandLaniyati Hamijoyo, IndonesiaTsutomu Takeuchi, JapanYan Zhao, ChinaZhanguo Li, ChinaJames Wei, TaiwanLai-Shan Tam, Hong KongKeith Lim, AustraliaSakae Tanaka, JapanDebasish Danda, IndiaMichael Tee, PhilippinesKatsunori Ikari, JapanChang-Fu Kuo, BangladeshAndrea Low, SingaporeRaja Jasmin, MalaysiaLau Tang Ching, SingaporeYeap Swan Sim, MalaysiaLisa Stamp, New ZealandChi-Chen Chang, Taiwan

Matt Brown, AustraliaJenni Ng, AustraliaLisa Cummins, AustraliaLinda Bradbury, AustraliaNavid Adib, AustraliaCharles Inderjeeth, AustraliaStephen Hall, AustraliaAshleigh Hennessey, AustraliaDavid Pennisi, AustraliaSamuel Whittle, AustraliaRanjeny Thomas, AustraliaIrwin Lim, Australia


FACULTY LISTING

Amita Aggarwal India

Anne Barton UK

Emma Bavage Australia

Kate Bell Australia

Helen Benham Australia

Kim Bennell Australia

Linda Bradbury Australia

Michael Brenner USA

Rachelle Buchbinder Australia

David Burgner Australia

Yew Kuang Cheng Singapore

Francesco Ciccia Italy

Flavia Cicuttini Australia

Rory Clifton-Bligh Australia

John Connolly Singapore

Diana Conrad Australia

Kay Crossley Australia

Nicola Dalbeth New Zealand

Debashish Danda India

Richard Day Australia

Kristen Demoruelle USA

Riccardo Dolcetti Australia

Emma Duncan Australia

Annamarie Fairhurst Singpapore

Mary-Ann Fitzcharles Canada

Ivan Foeldvari Germany

Helen Foster UK

Francesca Frentiu Australia

Stephen Hall Australia

Rohini Handa India

Malcolm Handel Australia

Syed Atiqul Haq Bangladesh

Alex Hewitt Australia

Catherine Hill Australia

David Hunter Australia

Annamaria Iagnocco Italy

John Isaacs UK

Tony Kenna Australia

Sankalp Khanna Australia

Hyun Ah Kim Korea

Lars Klareskog Sweden

Masataka Kuwana Japan

Richard Kwiatek Australia

Jisoo Lee Korea

Michelle Leech Australia

Ying Ying Leung Singapore

Linda Li Canada

Vidya Limaye Australia

Peter Lipsky USA

Andrea Low Singapore

Ingrid Lundberg Sweden

Suresh Mahalingam Australia

Tanya Major New Zealand

Stuart Mannering Australia

Lyn March Australia

Deborah Marshall Canada

Helena Marzo-Ortega UK

Rebecca Mason Australia

Seth Masters Australia

Iain McInnes Scotland

Ramnath Misra India

Eric Morand Australia

Ann Morgan UK

Lorimer Moseley Australia

Peter Nash Australia

Christopher Needs Australia

Allison Pettit Australia

Susanna Proudman Australia

Elaine Remmers USA

Maureen Rischmueller Australia

Lynden Roberts Australia

Phil Robinson Australia

Jamie Rossjohn Australia

Nivene Saad Australia

Sujata Sawhney India

Hans Ulrich Scherer Netherlands

Nan Shen China

Andreas Suhrbier Australia

Clair Sullivan Australia

Yoon-Kyoung Sung Korea

Lai-Shan Tam Hong Kong

Yoshiya Tanaka Japan

Ranjeny Thomas Australia

Rachel Thomson Australia

Xiaobing Wang China

Mihir Wechalekar Australia

Cheng-Chung Wei Taiwan

Ian Wicks Australia

Heather Wisbey Australia

Peter Wong Australia

Daniel Wright New Zealand

Huji Xu China

Dae Hyun Yoo Korea

Laurel Young Australia

Wen Zhang China

Zhuoli Zhang China


ABOUT BRISBANE Brisbane is the capital of the Sunshine State and with almost 300 days of sunshine per year, the city knows how to take advantage of the year-round outdoor lifestyle.

Extend your stay and see some more of Brisbane’s backyard. Discover the city through the eyes of a local, cuddle a koala and hand-feed kangaroos, watch the sun set from one of only three bridge climbs in the world and dine on tasty menus created using produce grown less than two hours from Brisbane.

Your Brisbane experience awaits...

Extend your stayGot some free time during your visit to Brisbane or thinking of extending your stay? See what incredible Brisbane experiences are on offer.

Where to eat & drink Whether you’re here to drink or dine, are a foodie or newbie, Brisbane’s restaurants, cafes and bars will satisfy.

Explore the region Brisbane is a city for the senses; walking under impossibly blue skies around this foot-friendly city find opportunities to eat, drink, shop, play and stay.

72 hours in BrisbaneLoosen the tie, ditch the heels and step out into our sun-dappled streets to discover Brisbane’s award-winning restaurants, cafes, quirky bars and must-see art galleries.

Brisbane Greeters The best way to discover a city with heart is to start with the people who know it best. Find out what makes Brisbane tick on a Brisbane Greeters tour.

Visitor essentialsGet to know Brisbane better. From climate to currency, from Wi-Fi to weather – we have you covered.


http://www.visitbrisbane.com.au/brisbane-greeters?utm_source=iFrame

http://www.visitbrisbane.com.au/brisbane-greeters?utm_source=iFrame

http://www.visitbrisbane.com.au/brisbane/things-to-do/tours-and-transport/story-bridge-adventure-climb?utm_source=iFrame

http://www.visitbrisbane.com.au/things-to-do/eat-and-drink?utm_source=iFrame

https://www.visitbrisbane.com.au/information/industry-toolbox/itineraries/pre-and-post-convention-touring

https://www.visitbrisbane.com.au/things-to-do/eat-and-drink

https://www.visitbrisbane.com.au/information/articles/destinations/30-things-to-do-brisbane-region

https://www.visitbrisbane.com.au/information/articles/activities/3-day-brisbane-itinerary?sc_lang=en-au

https://www.visitbrisbane.com.au/brisbane-greeters

https://www.visitbrisbane.com.au/information/visitor-essentials

https://www.visitbrisbane.com.au/information/industry-toolbox/itineraries/pre-and-post-convention-touring

https://www.visitbrisbane.com.au/things-to-do/eat-and-drink

https://www.visitbrisbane.com.au/information/articles/destinations/30-things-to-do-brisbane-region

https://www.visitbrisbane.com.au/brisbane-greeters

https://www.visitbrisbane.com.au/information/visitor-essentials

https://www.visitbrisbane.com.au/information/articles/activities/3-day-brisbane-itinerary?sc_lang=en-au


workshops




workshops



Download the APLAR 2019 app

Find this icon in the exhibition

Scan the icon using Start AR in the APLAR 2019 app

Follow to the APLAR 2020 Lounge for a chance to win!

Don’t miss your chance to win a free APLAR 2020 registration!

1

2

3

1

2

3

4

in your app store to download this tool onto your smartphone or tablet.

Download the app

Proud sponsor of the congress app

Login to the app

Personalise your app experience

Once downloaded, select APLAR 2019 in the app.

Go to the My Event icon on the second page and click ‘Log in’.

Enter your unique 7 digit access code found on your name badge.

Entering your unique code into the app will personalise this to you. You can connect with colleagues, schedule the sessions you would like to attend and more.

Please see our onsite app specialist with any questions on logging in or utilising the app whilst in Brisbane.

This is the official APLAR-ARA 2019 congress app for all registered attendees. It contains full program information, speaker list, social functions and industry program information.

Please follow the steps below to get the app, personalise this with your unique code, and enhance your APLAR-ARA 2019 Brisbane experience!

Search ‘APLAR’


CONGRESS VENUE APLAR-ARA 2019 will be held in the Brisbane Convention and Exhibition Centre (BCEC).

All BCEC floor levels are colour coded for ease of finding your way. The Plaza Level (red) is the link between BCEC on Merivale Street and BCEC Grey Street.

Exhibition Hall 4

Exhibition Hall 3

Exhibition Hall 2

Exhibition Hall 1

Foyer

Plaza Ballroom FoyerTo BCEC onMerivale St

Plaza Ballroom

P5

P6P7P8P9P10P11

Plaza Ballroom

Plaza Gallery

Plaza Terrace Room

Plaza Auditorium

P4P3

P2

P1

M3

M2

VIP Suite

M9 M8 M7 M6 M5

M1Great Hall

Upper Level

Great HallAPLAR-ARA 2019

Exhibition

APLAR-ARA 2019 Registration

Exhibition Hall 1

Main Entrance

Main Foyer

Glenelg Street

M4M10

Speaker Preparation Room

Escalators to Mezzanine Level

Escalators to Plaza Level

Escalators to Main Foyer

Escalators to Mezzanine

Level

Exhibition Halls 2–4

Exhibition Hall 4

Exhibition Hall 3

Exhibition Hall 2

Exhibition Hall 1

Foyer


Plaza Ballroom

P5

P6P7P8P9P10P11

Plaza Ballroom

Plaza Gallery

Plaza Terrace Room

Plaza Auditorium

P4P3

P2

P1

M3

M2

VIP Suite

M9 M8 M7 M6 M5

M1Great Hall

Upper Level


Exhibition


Exhibition Hall 1

Main Entrance

Main Foyer

Glenelg Street

M4M10






Level


Exhibition Hall 4

Exhibition Hall 3

Exhibition Hall 2

Exhibition Hall 1

Foyer


Plaza Ballroom

P5

P6P7P8P9P10P11

Plaza Ballroom

Plaza Gallery

Plaza Terrace Room

Plaza Auditorium

P4P3

P2

P1

M3

M2

VIP Suite

M9 M8 M7 M6 M5

M1Great Hall

Upper Level


Exhibition


Exhibition Hall 1

Main Entrance

Main Foyer

Glenelg Street

M4M10






Level


Plaza Level

Merivale Street & Glenelg StreetSouth Brisbane QLD 4101

Mezzanine Level Exhibition and Foyer Level


Registration informationThe congress registration desk will be located in the Main Foyer of the BCEC. The congress registration desk opening hours are outlined below:

Date Time

Monday 8 April 1100–1900

Tuesday 9 April 0700–1800

Wednesday 10 April 0700–1800

Thursday 11 April 0700–1630

For onsite registration enquiries, please visit us at the congress registration desk.

ExhibitionThe industry exhibition will be located in Exhibition Hall 1. The opening times for the exhibition are outlined below:

Date Time





WiFi accessEnjoy complimentary WiFi at BCEC for browsing the internet, checking emails or posting about your #APLAR19 experience on social media.

WiFi - APLAR2019Password - Brisbane2019

Tour deskA tour desk will be located at Exhibition Hall 1 and staffed during the hours outlined below:

Date Time




Speaker preparation roomThe speaker presentation room is located in room M10 of the Mezzanine level of the BCEC and will be open and staffed by professional AV technicians during the following times:

Date Time





This is a room specifically reserved for speakers and chairpersons to work on, load and practice their presentations/chairing duties prior to their program responsibilities.

All congress presentations will be networked to the relevant presentation room, therefore you need to ensure your presentation is loaded at least 3 hours prior to your speaking time. It will not be possible to use your own laptop or USB for your presentation in the congress concurrent sessions.

GENERAL INFORMATION

Exhibition Hall 4

Exhibition Hall 3

Exhibition Hall 2

Exhibition Hall 1

Foyer


Plaza Ballroom

P5

P6P7P8P9P10P11

Plaza Ballroom

Plaza Gallery

Plaza Terrace Room

Plaza Auditorium

P4P3

P2

P1

M3

M2

VIP Suite

M9 M8 M7 M6 M5

M1Great Hall

Upper Level


Exhibition


Exhibition Hall 1

Main Entrance

Main Foyer

Glenelg Street

M4M10






Level


Exhibition and Foyer Level

Registration deskMain Foyer, BCEC

ExhibitionHall 1, BCEC



workshops



Coffee breaksCatering will be served within Exhibition Hall 1 and will be available during the following times:

Date Break Time

Tuesday 9 April Morning tea 1000–1030

Afternoon tea 1545–1615

Wednesday 10 April Morning tea 1000–1030

Afternoon tea 1545–1615

Thursday 11 April Morning tea 1000–1030

Lunch breaksLunch will be served within Exhibition Hall 1. For delegates attending an industry lunch symposium, lunch will be served within the Great Hall.

Date Symposium Time

Tuesday 9 April Stay ahead of the game – Future approaches to spondyloarthropathies

1300–1430

Wednesday 10 April Pathways to better outcomes in rheumatic disease

1300–1430

Thursday 11 April The Management of Axial Spondyloarthritis – New advances and challenges

1230–1400

Poster presentationsPresenters who have pre-arranged poster printing with Snap South Brisbane will be able to collect posters from the congress registration desk located in the Main Foyer.

Posters will be displayed within the Exhibition Hall. Presenters are asked to stand by their posters during the morning, lunch and afternoon tea breaks of the scheduled presentation day to answer any questions regarding your work.

Poster toursOfficial poster tours in both English and Mandarin are scheduled for each lunch break. Attendees must pre-register to attend an official poster tour.

Poster tours are scheduled at the following times:

Date Language Time

Tuesday 9 April English 1300–1430

Mandarin 1300–1430

Wednesday 10 April English 1300–1430


Thursday 11 April English 1230–1400


If you would like to join a poster tour, please email [email protected] or visit the onsite registration desk to confirm availability.

Audio recordings of abstracts highlighted on each tour are available to listen to at any time through the congress app.

GENERAL INFORMATION


mailto:[email protected]

Prayer roomThe prayer room is located in VIP Suite 3 on the Mezzanine level and will be open Monday to Thursday between 0800-1700 hours.

LanguageThe official language of the congress is English.

Certificate of attendanceElectronic certificates of attendance will automatically be issued to all confirmed attendees at the conclusion of the congress.

Personal propertyPlease take good care of your personal belongings. Do not leave them unattended. The organisers and the congress secretariat will not be responsible for any loss or damage of your personal property. All items found or handed into the congress secretariat will be logged and kept by the BCEC onsite security team. If you believe you have lost property at the centre you can call +61 7 3308 3000 or fill out a general enquiry form.

Cloak roomsBCEC has two information desks which are located in the Grey Street and Merivale Street Foyers. The BCEC information desks offer cloak room facilities for your luggage, bags, prams or coats and will be available to access during the congress hours.

Parent roomsBCEC’s Parent Rooms feature all you need to feed and change in privacy and comfort. You can find Parent Rooms located on Merivale Street Main Foyer, just behind Merivales Cafe and one located on Grey Street Main Foyer next to the Information Desk. You will also find change tables in all of the uni-sex accessible toilets throughout the Centre.

Non-smoking venueBCEC is a non-smoking venue. Smoking within the venue is not permitted.

A designated smoking area is available on the external Plaza Terrace. Guests may smoke outside the venue keeping five metres clear of entry and exit doors.

The State of Queensland considers electronic, e-cigarettes, e-cigars and vape pens to be treated under the same regulations that apply to normal cigarettes. On the spot fines apply to users of these devices within the building or within five metres of entry and exit doors.

Medical emergenciesFor any medical emergencies please visit the congress registration desk or call +61 7 3308 3035.

GENERAL INFORMATION


https://www.bcec.com.au/lets-talk/

SOCIAL FUNCTIONS & CEREMONIES

Monday 8 April

Opening CeremonyDate: Monday 8 April 2019Time: 1700-1800Location: Great Hall, BCEC

Welcome ReceptionDate: Monday 8 April 2019Time: 1800-1930Location: Exhibition Hall 1Cost: Included in registration fee, USD 50 for accompanying person

Tuesday 9 April

Fun RunDate: Tuesday 9 April 2019Time: 0615Location: Southbank, BrisbaneMeeting point: Wheel of BrisbaneCost: Included in registration fee – FULLY BOOKED

Presidential DinnerDate: Tuesday 9 April 2019Time: 1930-2130Location: Rydges South BankCost: By invitation only


https://aplar2019.com/fun-run/

https://aplar2019.com/fun-run/

Tuesday 9 April

Paediatric Rheumatology Cocktail Party: Celebration of a Star!Date: Tuesday 9 April 2019Time: 1930-2130Location: Gambaro Seafood RestaurantAddress: 33 Caxton Street, Brisbane QLD 4000Cost: USD 60

RHP DinnerDate: Tuesday 9 April 2019Time: 1900-2130Location: Plough InnAddress: 29 Stanley St Plaza, South Brisbane QLD 4101Cost: At own expense on the night

Wednesday 10 April

Gala DinnerDate: Wednesday 10 April 2019Time: 1930-0000Location: Plaza Ballroom, BCECCost: USD 120

Thursday 11 April

Closing CeremonyDate: Thursday 11 April 2019Time: 1530-1615Location: Great Hall, BCEC

SOCIAL FUNCTIONS & CEREMONIES

Visit the Native Wildlife Display every day at lunch!Come and meet some of Australia’s furry and scaly locals.Tuesday 9 April: 1230–1500Wednesday 10 April: 1230–1500Thursday 11 April: 1200–1430


PRE-CONGRESS WORKSHOPS & COURSES

Sunday 7 April

Understanding MRI Imaging of the SI Joint – A Practical Course for CliniciansTime: 0800-1715Location: Room P5, BCECCost: USD 200

Click for more information

APLAR-ARA Clinical Review CourseTime: 0830-1545Location: Room P4, BCECCost: USD 25 – FULLY BOOKED


Immunology Review CourseTime: 0845-1700Location: Room 2003, Translational Research Institute, 37 Kent St, Woolloongabba QLD 4102Cost: USD 200


Sunday 7 April & Monday 8 April

Musculoskeletal Ultrasound (MSUS) WorkshopTime: 0930-1800 Sunday 7 April & 0830-1400 Monday 8 AprilLocation: Room P3, BCECCost: USD 400 delegates, USD 250 allied health professionals / trainee / student


Monday 8 April

Skin Score Training Workshop for Systemic SclerosisTime: 0830-1200Location: Room P6, BCECCost: Free to attend – FULLY BOOKED


Preceptorship CourseTime: 0830-1500Location: Room P1, BCECCost: Free to attend – FULLY BOOKED


Rheumatology Health Professionals WorkshopTime: 1000-1600Location: Room P4, BCECCost: Free for RHP members and USD 35 for non-members


Delegates must pre-register for all pre-congress workshops & courses. Please contact the congress registration team via email to [email protected] to secure your place in your preferred workshop/course.

For more details about each workshop, visit aplar2019.com/pre-congress-workshops


https://aplar2019.com/understanding-mri-imaging-of-the-si-joint-a-practical-course-for-clinicians/

https://aplar2019.com/aplar-ara-clinical-review-course/

https://aplar2019.com/immunology-review-course/

https://aplar2019.com/pre-congress-musculoskeletal-ultrasound-msus-workshop/

https://aplar2019.com/skin-score-training-workshop-for-systemic-sclerosis/

https://aplar2019.com/trainee-preceptorship-and-aplar-young-rheumatologists-session/

https://aplar2019.com/rheumatology-health-professionals-association-rhpa-workshop/


https://aplar2019.com/pre-congress-workshops/

INDUSTRY PROGRAM

Delegates must pre-register for the industry workshops on Monday 8 April.

Please contact the congress registration team via email to [email protected] to secure your place in your preferred workshop.

Pre-congress workshops - Monday 8 April

An Interactive Case Study Master Class for the Treatment of Axial Spondyloarthropathy Led by Australian and European Experts

Time: 0900-1700Room: P5FULLY BOOKED


Navigating the Vessel of VasculitisTime: 1330-1700Room: P6


Clinical Case Series in SpondyloarthropathiesTime: 1330-1700Room: P7


Industry symposia - Tuesday 9 April

Ways to Advance Rheumatic Care in Australia and Taiwan: A Holistic Approach

Time: 1030-1145Room: Great Hall


Emerging Targets in Chronic Pain: Understanding Nerve Growth Factor (NGF)

Time: 1030-1145Room: M1 & M2


Osteoporosis Treatments: Starting, Sequencing and Stopping – What is the Long-Term Outlook?

Time: 1030-1145Room: P1 & P2


Rheum for Improvement? The Increasing Role of RWE in Decision MakingTime: 1030-1145Room: P3, P4, & P5




https://aplar2019.com/industry-program/industry-workshop-an-interactive-case-study-master-class-for-the-treatment-of-axial-spondyloarthropathy-led-by-australian-and-EU-experts

https://wp.me/P9Sa0Y-wQ

https://aplar2019.com/industry-workshop-clinical-case-series-in-spondyloarthropathies/

https://aplar2019.com/industry-symposium-ways-to-advance-ra-care-in-australia-and-taiwan-a-holistic-approach/

https://aplar2019.com/industry-symposium-emerging-targets-in-chronic-pain-understanding-nerve-growth-factor-ngf/

https://aplar2019.com/industry-symposium-osteoporosis-treatments-starting-sequencing-and-stopping-what-is-the-long-term-outlook/

https://aplar2019.com/industry-symposium-rheum-for-improvement-the-increasing-role-of-rwe-in-decision-making/

Tuesday 9 April

Stay Ahead of the Game – Future Approaches to Spondyloarthropathies



Breaking New Ground in Rheumatology: We Haven’t Come This Far, to Only Come This FarTime: 1755-1855Room: P1 & P2 + P3, P4, & P5


Wednesday 10 April

A New Treatment Option for PsA Patients

Time: 1030-1145Room: M1 & M2


Redefining Your Practice with Infliximab BiosimilarTime: 1030-1145Room: P1 & P2


The Spondyloarthritides – New Data, More Options, Evolved Thinking – What’s in it for the Patient?Time: 1030-1145Room: P3, P4 & P5


Pathways to Better Outcomes in Rheumatic DiseaseTime: 1300-1430Room: Great Hall


INDUSTRY PROGRAM


https://aplar2019.com/industry-symposium-stay-ahead-of-the-game-future-approaches-to-axial-spondyloarthropathy/

https://aplar2019.com/industry-symposium-breaking-new-ground-in-rheumatology-we-havent-come-this-far-to-only-come-this-far/

https://aplar2019.com/industry-symposium-a-new-treatment-option-for-psa-patients/

https://aplar2019.com/industry-symposium-redefining-your-practice-with-infliximab-biosimilar/

https://aplar2019.com/industry-symposium-the-spondyloarthritides-new-data-more-options-evolved-thinking-whats-in-it-for-the-patient/

https://aplar2019.com/industry-symposium-pathways-to-better-outcomes-in-rheumatic-disease/

Thursday 11 April

The Management of Axial Spondyloarthritis – New Advances and Challenges



INDUSTRY PROGRAM


https://aplar2019.com/industry-symposium-the-management-of-axial-spondyloarthritis-new-advances-and-challenges/

CONGRESS PROGRAM

Wed 10 AprMon 8 Apr Thurs 11 AprTues 9 Apr

Monday 8 AprilRoom Great Hall

1700–1800 Opening Ceremony

Room Exhibition Hall

1800–1930 Welcome Reception and Sponsor acknowledgementOpening of Exhibition Hall

Tuesday 9 April0615 Fun Run - The Wheel of Brisbane, South Bank ParklandsRoom Great Hall M1 & M2 P1 & P2 P3, P4 & P5Chairs Debashish Danda, Wendy Stevens Jenni Ng, Nazrul IslamTopic Vasculitis Meet the Experts: Vasculitis Evidence into Practice0730–0800 Catherine Hill

Giant Cell Arteritis Pathogenesis and Management

Wen Zhang Lorimer MoseleyExplaining Pain to People with Arthritis

0800–0830 Alex HewittEmerging Molecular and Genetic Insights into Giant Cell Arteritis

Room Great HallChairs Peter Nash, Nicola Dalbeth0830–0915 Plenary Session I: Early Intervention in Rheumatoid Arthritis

John IsaacsRheumatoid Arthritis Early Diagnosis and Intervention

0915–1000 Plenary Session II: Precision Medicine in Rheumatoid ArthritisAnne BartonTreatment Response Prediction in Rheumatoid Arthritis

1000–1030 Coffee Break & Poster Viewing – Exhibition Hall 1030–1145 Industry Symposium Sponsored by

Bristol-Myers SquibbIndustry Symposium Sponsored by Pfizer

Industry Symposium Sponsored by Amgen

Industry Symposium Sponsored by Janssen

Chairs Graeme Jones, Tang Ching Lau Tony Kenna, Huji Xu Charles Inderjeeth, Syed Atiqul Haq Navid Adib, Ramnath MisraTopic Osteoporosis 1 Immunotherapy Health Economics, Constructing

Better Models of CarePaediatric Rheumatology

1145–1210 Emma Duncan Genetics and New Therapies in Osteoporosis

Hugh ReidMolecular Basis for MHC-peptide Interactions with T-cells

Lyn MarchThe Global Burden of Disease

Amita AggarwalJuvenile Spondyloarthritis

1210–1235 Allison Pettit Stem Cells and Osteoporosis

Ranjeny ThomasAntigen-specific Immunotherapy for Autoimmune Rheumatic Diseases

Deborah MarshallPatient Preferences in Decision Making

Helen FosterTackling the burden of musculoskeletal disease in children; working together and a call to action

1235–1300 Yoon-Kyoung SungNew Advances for the treatment of Glucocorticoid Induced Osteoporosis

Stuart ManneringAntigen Discovery - Lessons from T1D

Helen BenhamTelehealth and Rheumatology

Ivan FoeldvariUveitis in Children

Room Great Hall1300–1430 Industry Symposium Sponsored by Novartis1300–1430 Lunch Break & Poster Tours (English & Mandarin) – Exhibition HallChairs Paul Bird, Priscila Wong Heather Wisbey, Prasanta Padhan Ghita Harifi, Lisa Cummins Sakae TanakaTopic Spondyloarthritis 1 Scleroderma 1 Pregnancy, Breast-Feeding &

ArthritisAbstract Presentations

1430–1455 Cheng-Chung WeiTreatment Advances in Axial Spondyloarthritis

Andrea LowChallenges in the Diagnosis and Management of Pulmonary Hypertension in Systemic Sclerosis

Jisoo LeeDisease Burden of SLE in Women

Stephen HallSafety of Baricitinib: Update from up to 6 years of Treatment in Rheumatoid Arthritis Clinical Trials

Julia New-TolleyThe Utility of the ERS-RA Cardiovascular Risk Calculator in Australian Rheumatoid Arthritis patients

Chi Chiu MokPrevalence and Risk Factors of Serious Infections in Rheumatoid Arthritis Patients Receiving the Biologic/Targeted Synthetic DMARDs

Woo-Joong KimKidney Protective Effects of Urate-Lowering Therapy in Patients with Gout

1455–1520 Lai-Shan TamTreating Spondyloarthritis to Target- Are we Ready?

Ivan FoeldvariJuvenile Scleroderma

Peter WongVaccines and Arthritis


1520–1545 Ramnath MisraManagement of Reactive Arthritis

Susanna ProudmanManagement Issues in Scleroderma

Laurel YoungPregnancy and Arthritis

Philip RobinsonColchicine Prophylaxis of Gout Flares When Commencing Allopurinol is Very Cost Effective

Kathleen TymmsImpact of Anti-citrullinated Protein Antibody on Response to Abatacept and TNFi in Patients with Rheumatoid Arthritis in the OPAL Dataset

Manoranjan BeheraCharcot Arthropathy Caused by Syringomyelia and Chiari-Malformation: A Rare Case Series

Hiroki FuruyaAn Important Differential Diagnosis of SAPHO Syndrome: Disseminated Nontuberculous Mycobacterial Infection with Neutralizing Anti-IFNγ Autoantibody in Apparently Immunocompetent Patient

Andrisha InderjeethComparing the Electronic Patient Reported Outcome (ePro) Tool Versus the Paper Reported Outcome (pPro) Tool in Rheumatoid Arthritis Patients

1545–1615 Coffee Break & Poster Viewing – Exhibition Hall Chairs Ian Wicks Catherine Hill, Leslie Schreiber Peter Sternes, Helen Benham Richard Kwiatek, Sam WhittleTopic American College of Rheumatology

SymposiumVasculitis Microbiome and Rheumatic

DiseasesPain in Rheumatology - Diagnosis & Management

1615–1640 1615–1650Peter LipskyBig Data and Novel Drug Development for SLE

David BurgnerKawasaki Disease Pathogenesis and Management

Huji XuMicrobiome Studies in Ankylosing Spondylitis

Lorimer MoseleyContemporary Pain Care: Be Excited (and Open Minded and Brave…)

1640–1705 1650–1730Michael BrennerNew concepts for T cells and stromal cells in rheumatoid arthritis

Debashish DandaNew Advances in Takayasu Arteritis, Asia-Pacific Data and Collaborative Work

Francesco CicciaThe Gut and Ankylosing Spondylitis

Lynden RobertsThe 2019 Rheumatologist’s Back Pain Handbook

1705–1730 Wen ZhangIgG4 Vasculitis Pathogenesis and Management

Kristen DemoruelleRheumatoid Arthritis Lung and Genital Tract Microbiome

Mary-Anne FitzcharlesShould Rheumatologists See Patients with Fibromyalgia and Prescribe Marijuana?

Room P1 & P2 and P3, P4 & P51755–1855 Industry Symposium Sponsored by AbbVie


CONGRESS PROGRAM

Room Rydges South Bank Gambaro Seafood Restaurant Plough Inn1930–2130 Presidential Dinner

(by invitation only)Paediatric Rheumatology Cocktail Party(1900 start)

Rheumatology Health Professionals Dinner (1900 start)



Wednesday 10 AprilRoom Great Hall M1 & M2 P1 & P2 P3, P4 & P5 P6Chairs Sunith Himantha Atukorale, Sam

WhittleSean O’Neill, Kevin Pile Paul Kubler, Stephen Hall

Topics Evidence-Based Medicine Meet the Experts: Systemic Lupus Erythematosus, Sjogren’s and Scleroderma

Biologics in Developing Countries – Economics and Infections

Improving Bang for the Buck in Trialling Therapeutics for the 21st Century

0730–0800 Rachelle BuchbinderThe Lancet – Low Back Pain Series: A call to action to address this major global health challenge

John Reveille and Susanna Proudman

Syed Atiqul HaqBiologics and Developing Countries

John ConnollyImmune Biomarker Development

Topics Osteoarthritis Managing Biologics in Practice John IsaacsSmart Trial Designs0800–0830 David Hunter

Novel Therapies for OsteoarthritisEmma BavagePatients, Paper and the PBS- What Could Go Wrong?

Room Great HallChairs Christina Boros, Geoff McColl0830–0915 Plenary Session I: Early Intervention

Helena Marzo-OrtegaAxial Spondyloarthritis - Costs and Benefits of Early Treatment

0830–1030APLAR SIG Group Leaders Meeting0915–1000 Plenary Session II: Paediatric Rheumatology

Helen FosterTransitional Care for Young People with Juvenile Idiopathic Arthritis - Getting it Right

1000–1030 Coffee Break & Poster Viewing – Exhibition Hall 1030–1145 Industry Symposium Sponsored

by PfizerIndustry Symposium Sponsored by Celltrion

Industry Symposium Sponsored by UCB

Chairs Indi Rasaratnam Muriel Soden, Ramnath Misra Francesco Ciccia, Matt Brown Michelle Leech, Irwin LimTopics Crystal Disease Viral Arthritis Autoinflamatory Diseases Abstract Presentations1145–1210 Daniel Wright

Allopurinol – How to get the Dose right

Andreas SuhrbierRoss River Fever

Dae Hyun YooTreatment of Adult Onset Stills Disease

Zhixiu LiGWAS of Ankylosing Spondylitis Identifies New, Druggable, Susceptibility Loci

Xiufeng HuangGenomewide association study of acute anterior uveitis identifies new susceptibility loci

Masami OgasawaraThe characteristics, trend of frequency and outcome of reactive arthritis in Japanese patients with bladder cancer following intravesical BCG therapy

Milica OgnjenovicMortality in Hospitalised Ankylosing Spondylitis Patients from Western Australia

Ajit Kumar SurinIgA Nephropathy in a Female Patient with Spondyloarthropathy Masquerading as Poncets Disease (or Extrapulmonary TB): A Case Study

Benny Samuel Eathakkattu AntonyMagnetic Resonance Imaging Markers Improve the Prediction Model for Total Knee Replacement Over 13 Years in Older Adults

Charles InderjeethA Hospital Based Fracture Liaison Service Effectively Reduces Re-Fracture, Is Cost-Effective and Improves QALY

Helen FosterPaediatric Musculoskeletal (MSK) Triage in the Community – RightPath – A Pilot Study

Dongze WuGlobal, Regional, and National Burden of Psoriatic Disease Estimates From The Global Burden of Disease 2016 Study

1210–1235 Nicola DalbethControversies in Gout Management

Francesca FrentiuZika Virus

Elaine RemmersBehcets Disease

1235–1300 Tanya MajorPrecision Medicine for Gout

Suresh MahalingamChikungunya Virus

Seth MastersPyrinopathies

Room Great Hall1300–1430 Industry Symposium Sponsored by Lilly1300–1430 Lunch Break & Poster Tours (English & Mandarin) – Exhibition Hall

CONGRESS PROGRAM


Chairs Yoshiya Tanaka Eric Morand, Ranjeny Thomas David Careless, Linda Bradbury Lyn March, Zeng Xiaofeng 1430–1700APLAR Inaugural Annual General Assembly*registration from 1400

Topics Systemic Lupus Erythematosus Hot Immunology Spondyloarthritis 2 Social Media and Digital Health in Research and Clinical Practice

1430–1455 Anna-Marie FairhurstTLR7 and SLE Novel Therapeutics

Riccardo DolcettiThe Revolution in Cancer Immunotherapies

Diana ConradUveitis in Spondyloarthritis

Sankalp KhannaArtificial Intelligence and Machine Learning Techniques Optimising Patient Management

1455–1520 Sujata SawhneySystemic Lupus Erythematosus in Asians

Abstract Presentations

Yi Tian TingThe Interplay Between Citrullination of Self-epitopes and HLA Polymorphism that Shape Peptide HLA Binding Affinity in Rheumatoid Arthritis

Dario RoccatelloEffects of an Intensive B-cell Depletion Treatment of Severe Systemic Sclerosis

Dario RoccatelloCase-Control Study on the Cyclophosphamide-Sparing Effects of an Intensified B-Cell Depletion Treatment of Anca-Associated Vasculitis

Anthony SammelThe Diagnostic Accuracy of PET/CT compared with Temporal Artery Biopsy for Giant Cell Arteritis (GCA)

Xiaojie Jeremy WangPneumocystis jiroveci Pneumonia is Associated with Rituximab and Gastroeosophageal Reflux Disease in Rheumatic Disease Cohort: A Retrospective Study

Muhammad Shoaib Momen MajumderAL Amyloidosis Presenting as Inflammatory Polyarthritis: A Case Report

Peter NashNew Treatments for PsA

Clair SullivanUsing the Digital Health Record to Improve Clinical Outcomes

1520–1545 Nan ShenEvolving Understanding of Genetic and Epigenetic Control of Innate Immunity in SLE

Masataka KuwanaAre we on the Verge of Cracking the Nut in Systemic Sclerosis?

Ying Ying LeungOutcomes in Psoriatic Arthritis - What should we Measure in the Clinic?

Linda LiRheumatology in the Digital Age

1545–1615 Coffee Break & Poster Viewing – Exhibition Hall Chairs David Nicholls, Yeong-Wook Song Ann Barton, Ranjeny Thomas Geraldine Zamora Racaza,

Andrea LowEmma Duncan, Rob Will

Topics EULAR Symposium Functional Autoantibodies Myositis Osteoporosis 21615–1640 1615–1650

Iain McInnesTreatment of Rheumatoid Arthritis - What Will the Next Decade Bring?

Lars KlareskogRole of ACPAs in the gradual evolution of seropositive RA

Vidya LimayePulmonary involvement in inflammatory myositis

Kate BellFracture Liaison Services

1640–1705 Hans Ulrich SchererACPA Glycosylation as Biomarker in Rheumatoid Arthritis


Anthony SammelThe Diagnostic Accuracy of PET/CT Compared with Temporal Artery Biopsy for Giant Cell Arteritis (GCA)

Xiaojie Jeremy WangPneumocystis jiroveci Pneumonia is Associated with Rituximab and Gastroeosophageal Reflux Disease in Rheumatic Disease Cohort: A Retrospective Study

Muhammad Shoaib Momen MajumderAllied health: Case Report

Rachelle BuchbinderVertebral Fractures: Controversies in Definition and Management

Topics 1650–1730Annamaria IagnoccoImaging, T2T and Rheumatoid Arthritis

Precision Medicine in Rheumatoid Arthritis

Ingrid LundbergCurrent Classification and Management of Myositis

Rebecca MasonVitamin D in Human Health and Disease1705–1730 Mihir Wechalekar

Clinical Uses of Synovial Biopsies in Inflammatory Arthritis

1730–1830 ARA AGM1930–0000 Gala Dinner – Plaza Ballroom


CONGRESS PROGRAM



Thursday 11 AprilRoom Great Hall M1 & M2 P1 & P2 P3, P4 & P5

Chairs Anita Lee, Chi-Chen Chang Nicola Dalbeth, Phil Robinson Lynden Roberts, Johannes Nossent

Topics Developments in Imaging Meet the Experts: Chronic Pain Crystal Disease 2 Sjogren’s Disease0730–0800 Nivene Saad

MRI in Inflammatory Arthritis - Should we stop doing Xrays?

Mary-Ann Fitzcharles and Christopher Needs

Richard DayStrategies to Improve Gout Management

Maureen RischmuellerManagement of Sjogren’s Disease

0800–0830 Zhuoli ZhangUltrasound in Arthritis

Rory Clifton-BlighFGF23, Bones and Joints

Xiaobing WangAsian Sjogren’s Disease

Room Great HallChairs Nan Shen, Susanna Proudman0830–0915 Plenary Session I: Systemic Lupus Erythematosus

Yoshiya TanakaNovel Agents in Lupus

0915–1000 Plenary Session II: Precision Medicine in SLEEric MorandNovel Biomarkers

1000–1030 Coffee Break & Poster Viewing – Exhibition Hall Chairs Kazuhiko Yamamoto, Ranjeny

ThomasHelen Keen Mandana Nikpour Ved Prakash Chaturvedi, Mark

ArnoldTopics Year in... Osteoarthritis Scleroderma 2 Rheumatology Workforce

Training1030–1100 CLINICAL Year in Review

Michelle LeechFlavia CicuttiniOsteoarthritis Pathogenesis

Heather WisbeyLung Disease and Scleroderma

Amita AggarwalRheumatology in India

1100–1130 RESEARCH Year in ReviewHuji Xu

Hyun Ah KimOsteoarthritis: What, and What Not, to Treat

Andrea LowScleroderma in Asia

Malcolm HandelRheumatology, Research and Industry

1130–1200 CLINICAL Year in PreviewLai-Shan Tam

Kay CrossleyEducation and Exercise for Knee OA: Making it Work in Clinical Practice


Vera GolderTreat to Target in SLE – Comparison of Remission and Lupus Low Disease Activity State in a Multinational Prospective Study

Chi Chiu MokOutcome of Stroke in Patients with Systemic Lupus Erythematosus: a Nested Case-control Study

Rachel KoelmeyerGetting to the Bones of It: A Clinical Audit of Osteoporosis Management in an Australian SLE Cohort

Biyu ShenThe emotional experience of patients with Systemic Lupus Erythematosus-related Body Image disorder in China: A qualitative study

Syed Atiqul HaqAPLAR Workforce Issues

1200–1230 RESEARCH Year in PreviewIan Wicks

Kim BennellOnline Approaches to the Delivery of Lifestyle Treatments for Osteoarthritis

Tony KennaGenetics in Scleroderma and New Disease Targets

Linda BradburyThe Role of the Nurse in Rheumatology Care

Room Great Hall1230–1400 Industry Symposium Sponsored by Janssen1230–1400 Lunch Break & Poster Tours (English & Mandarin) – Exhibition HallChairs Stephen Hall, Yew Kuang Cheng1400–1530 Grand Rounds

Charles InderjeethMental Impairment and the Rheumatologist

Khai Jing NgJust When You Thought It Was Safe to go into the Water

Victoria Johnson300% of Nothing

Xiaoying SunThe Eyes Have It

Alannah QuinlivanA Case of Abdominal Pain

Daniya ChaudhryA Dress is Not a Dress

1530–1615 Closing Ceremony

CONGRESS PROGRAM


POSTER PRESENTATIONS


POSTER TOURS

Tuesday 9 AprilPoster Paper title Presenting Author

1 THE USE OF COMPLEMENTARY AND ALTERNATIVE MEDICINE BY RHEUMATOID ARTHRITIS PATIENTS IN A UNIVERSITY HOSPITAL CLINIC IN INDIA

Panna Mishra

2 REFRACTORY VASCULITIC LEG ULCERS IN A CLINICALLY QUIESCENT SYSTEMIC LUPUS ERYTHEMATOSUS PATIENT,DIAGNOSTIC AND MANAGEMENT QUANDARY: A CASE REPORT

Duminda Abeysinghe

3 EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS WITH MONONEURITIS MULTIPLEX – A CASE REPORT Charlie Jr. Chan5 CASE REPORT: RITUXIMAB IN A CASE OF DERMATOMYOSITIS COMPLICATED BY DIFFUSE ALVEOLAR HEMORRHAGE Ana Monica Estrella6 A CASE OF SYSTEMIC LUPUS ERYTHEMATOSUS WITH ENCHEPALITIS ANTI-NMDAR INDUCED BY TERATOMA Pande Ketut Kurniari

7 PATIENTS ENROLLED IN AN ANKYLOSING SPONDYLITIS (AS-P) PATIENT CENTRED EDUCATION PROGRAM HAD IMPROVED DISEASE ACTIVITY OUTCOMES UP TO 12 MONTHS

Charles Inderjeeth

8 FORMULATION AND CHARACTERIZATION OF NAPROXEN NIOSOMES Nafiseh Abdolahi9 PREPARATION OF NANO COMBINATION NAPROXEN-SULFASALAZIN Nafiseh Abdolahi

10 DISTINCTIVE METABOLIC SIGNATURES OF AXIAL AND PERIPHERAL ANKYLOSING SPONDYLITIS REVEALED BY 1H NMR BASED SERUM METABOLOMICS

Amita Aggarwal

11 MIR-326 IMPROVES TH17/TREG IMBALANCE IN LUPUS NEPHRITIS OF MRL/LPR MICE Xuan Fang12 MIR-326 REGULATES CD4+T CELLS DIFFERENTIATION IN SYSTEMIC LUPUS ERYTHEMATOUS Xuan Fang13 ALTERATIONS OF IMMUNE CELL SUBSETS IN PATIENTS WITH MIXED CONNECTIVE TISSUE DISEASE Junko Maeda14 THE GENE EXPRESSIONS OF VARIOUS KEY MOLECULES ARE INFLUENCED BY FAS LIGAND IN RHEUMATOID SYNOVIAL FIBROBLASTS Koji Fukuda

15 AN IMMUNOSEQUENCING APPROACH TO INTERROGATING THE T-CELL RECEPTOR REPERTOIRE IN ANKYLOSING SPONDYLITIS PATIENTS

Aimee Hanson

16 AUTOIMMUNE RHEUMATOLOGICAL DISORDERS AND MUTATION PROFILE OF CONCOMITANT MYELODYSPLASTIC SYNDROME Lih En Hong17 CCL17 IN SYNOVIAL FLUID AND PLASMA OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS Cecil Hor

18 OSTEOPOROSIS AND DEMENTIA COMMON PATHWAYS AND TARGETS: A MOUSE MODE INVESTIGATING THE EFFECT OF ACETYLCHOLINE ESTERASE INHIBITOR DONEPEZIL ON BONE

Charles Inderjeeth

19 COMBINED TLR4 (ASP299GLY) AND CD14 (C-159) VARIANTS ARE ASSOCIATED WITH SUSCEPTIBILITY TO AOSD: A CASE-CONTROL STUDY IN ODISHA, INDIAN PATIENTS

Sweekruti Jena

20 SUCCESSFUL TREATMENT OF REFRACTORY ERYTHEMA NODOSUM WITH ORAL POTASSIUM IODIDE IN A PATIENT WITH CHRONIC LIVER DISEASE. AN OLD DRUG REINVENTED

Shaloo Bhasin

21 SERUM ALDOLASE: A USEFUL MARKER OF DIAGNOSIS AND DISEASE ACTIVITY IN PATIENTS WITH ADULT-ONSET STILL’S DISEASE Shinji Izuka

22 A COMPARATIVE STUDY OF VITAMIN D SERUM LEVELS BETWEEN PATIENTS WITH RECURRENT APHTHOUS STOMATITIS AND NORMAL SUBJECTS

Nasrin Moghimy

23 AN INTERDISCIPLINARY DIAGNOSTIC CHALLENGE: A CASE OF ATYPICAL COGAN’S SYNDROME Mollyza Mohd Zain24 USEFULNESS OF TACROLIMUS FOR ADULT-ONSET STILL’S DISEASE: SINGLE-CENTER HISTORICAL COHORT STUDY Hiroyuki Nakamura25 AGGRESSIVE NK CELL LEUKEMIA MASQUERADING AS BEHÇET’S DISEASE Khai Jing Ng

26 DYSKERATOTIC CELLS IN PERSISTENT PRURITIC SKIN LESIONS ARE APOPTOTIC AND ASSOCIATED WITH HIGH LEVELS OF SERUM IL-18 Hirofumi Nishikawa

27 CLINICAL CHARACTERISTICS OF PATIENTS WITH REMITTING SERONEGATIVE SYMMETRICAL SYNOVITIS WITH PITTING EDEMA COMPARED TO PATIENTS WITH ELDERLY-ONSET RHEUMATOID ARTHRITIS

Tomoki Origuchi

28 CALF PAIN AS A PROMINENT FEATURE OF BEHCET’S DISEASE: FOUR CASE REPORTS Grace Penserga29 CONCURRENCE OF BECHET’S DISEASE, INCONTINENTIA PIGMENTI AND ECTOPIC KIDNEY IN A YOUNG FILIPINO WOMAN Grace Penserga

30 AMYLOIDOSIS: A MIMIC OF RHEUMATIC CONDITION Azwarina Hanim Ramlan

31 THE RATIO OF SERUM MMP-3 TO CRP IS USEFUL FOR DISTINGUISHING PMR-MIMICKING EORA FROM TRUE PMR AT THE ONSET Takeshi Suzuki32 PREVALENCE OF ANTIPHOSPHOLIPID ANTIBODIES IN WOMEN WITH EARLY ONSET PREECLAMPSIA IN A TERTIARY CENTRE Aoife Sweeney33 MYELOPROLIFERATIVE NEOPLASM IN A 36YEAR OLD FEMALE WITH BEHCETS DISEASE:A CASE REPORT Jimmy Gene Villo

35 N-ACETYLTRANSFERASE 2 (NAT2) ACETYLATOR STATUS AND ORGAN INVOLVEMENT AMONG SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS FROM INDONESIA

Laniyati Hamijoyo

36 NEXT-GENERATION SEQUENCING OF THE WHOLE MEDITERRANEAN FEVER GENE IN 266 JAPANESE PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER: A CASE-CONTROL ASSOCIATION STUDY

Tomohiro Koga

37 FINE-MAPPING OF THE NPEPPS LOCUS ASSOCIATED WITH ANKYLOSING SPONDYLITIS SUSCEPTIBILITY IN A EUROPEAN COHORT William Midwinter38 THE ASSOCIATION BETWEEN KNEE OSTEOARTHRITIS AND COFFEE CONSUMPTION IN ELDERLY KOREANS Sung Jae Choi39 IMPACT OF FRAX-BASED OSTEOPOROSIS TREATMENT IN PATIENTS WITH OSTEOARTHRITIS Sung-Soo Kim41 OSTEOARTHRITIS IN A COMMUNITY BASED RHEUMATOLOGY PRACTICE: PATTERN, SECULAR AND TEMPORAL TRENDS 2007-2017 Bharat Manchanda43 THE LACK OF ASSOCIATION BETWEEN KNEE EFFUSION SIZE AND RADIOGRAPHIC SEVERITY IN KNEE OSTEOARTHRITIS Chris Pham44 MORTALITY RATES IN PATIENTS WITH OSTEOARTHRITIS IN WESTERN AUSTRALIA FROM 1995-2015 Warren Raymond

45 AYURVEDIC DRUGS AND CELECOXIB SHOW SUPERIOR CHONDROPROTECTIVE EFFECT COMPARED TO GLUCOSAMINE : A CONTROLLED RADIOLOGICAL EVALUATION IN SYMPTOMATIC OSTEOARTHRITIS KNEE

Manjit Saluja

46 ISORHAMNETIN AMELIORATES INFLAMMATORY RESPONSES AND ARTICULAR CARTILAGE DAMAGE IN THE RATS OF MONOSODIUM IODOACETATE-INDUCED OSTEOARTHRITIS

Deng-Ho Yang

47 CORRELATION OF SERUM MMP-3 LEVELS WITH TIME COURSE AFTER THE ONSET OF RAPIDLY PROGRESSIVE OSTEOARTHRITIS OF THE HIP

Tadashi Yasuda

49 AUSTRALIAN OSTEOPOROTIC TREATMENT TRENDS OVER FIVE YEARS Ravini Gunawardana

50 GARVAN FRACTURE RISK CALCULATOR WITHOUT BMD IS ACCURATE AND REDUCES RELIANCE ON BMD IN OLDER PEOPLE WITH POOR ACCESS

Charles Inderjeeth

51 OSTEOPOROSIS IN DEMENTIA PATIENTS: IF POORLY MANAGED RESULTS IN HIGH MORBIDITY AND MORTALITY Andrisha Inderjeeth

52 SERUM INTERLEUKIN 17 (IL-17) LEVELS CORRELATED WITH NUCLEAR FACTOR–KAPPA B LIGAND (RANKL) IN PATIENTS WITH SYSTEMIC LUPUS ERITHEMATOSUS

Gede Kambayana

Posters being presented during the official English and Mandarin poster tours are highlighted in blue.



53 A REGULATORY ROLE OF ANTXR1 IN RANKL-INDUCED OSTEOCLAST DIFFERENTIATION AND FUNCTION Myeung Su Lee54 THE STUDY OF PREDICTORS OF OSTEOPOROTIC FRACTURE IN RHEUMATOID ARTHRITIS Panna Mishra55 AN AUDIT ON CORTICOSTEROID MANAGEMENT AMONG RHEUMATOLOGY PATIENTS IN A TERTIARY HOSPITAL Armi Salonga

56 HOW HAS TREATMENT OF OSTEOPOROTIC CHANGED IN THE NEW DECADE? OUR EXPERIENCE IN A TERTIARY RHEUMATOLOGY CENTRE IN MALAYSIA

Phing Sue Wong

57 CHILDHOOD SYSTEMIC LUPUS ERYTHEMATOUS IN THE WESTERN AUSTRALIAN POPULATION I: CLINICAL AND LABORATORY CHARACTERISTICS

Anne Sage

58 CHILDHOOD SYSTEMIC LUPUS ERYTHEMATOUS IN THE WESTERN AUSTRALIAN POPULATION II: MANAGEMENT AND OUTCOMES Megan Cann

59 PREVALENCE OF LOW BONE MASS AMONG CHILDREN AND ADOLESCENTS WITH JUVENILE IDIOPATHIC ARTHRITIS IS LOW: A STUDY FROM THAILAND

Sirirat Charuvanij

60 CHILDHOOD ONSET SYSTEMIC LUPUS ERYTHEMATOSUS: PATTERN OF INITIAL CLINICAL MANIFESTATIONS IN A PAKISTANI POPULATION

Sumaira Farman

61 GLOBALISATION OF PAEDIATRIC MUSCULOSKELETAL MATTERS Helen Foster62 THE ROLE OF 5-METHOXYTRYPTOPHAN (5-MTP) IN PEDIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS WITH NEPHRITIS Jing-Long Huang

63 THIRD DEGREE AV BLOCK IN AN ADOLESCENT WITH ACUTE RHEUMATIC FEVER: A CASE REPORT Mae Fairlenn Carmel Jocson

64 LONG TERM SAFETY AND EFFICACY OF ETANERCEPT IN JUVENILE IDIOPATHIC ARTHRITIS: A SINGLE-CENTER EXPERIENCE IN KOREA Kwang Nam Kim65 MOYAMOYA SYNDROME IN A 16 YEAR OLD FILIPINO FEMALE WITH ACTIVE SLE: A CASE REPORT Michelle Gale Mejia

66 REMISSION TARGETS AND PREVENTION OF SUBCLINICAL ATHEROSCLEROSIS IN PSORIATIC ARTHRITIS- WHICH TARGET SHOULD WE CHOOSE?

Tsz Ho Cheng

67 UTILITY OF THREE DIFFERENT PSORIASIS-RELATED SCREENING TOOLS TO SCREEN FOR PSORIATRIC ARTHRITIS IN AN OUTPATIENT SETTING

Praveena Chiowchanwisawakit

68 PREVALENCE OF PSA AMONGST SECUKINUMAB TREATED PSO PATIENTS IN THE AUSTRALIAN SETTING: A SUB ANALYSIS FROM THE PHASE IV HOPE STUDY

Peter Foley

69 COMORBIDITIES IN PSORIATIC ARTHRITIS PATIENTS IN THE UAE Ghita Harifi

72 SYSTEMATIC REVIEW OF DEPRESSION AND ANXIETY IN PSORIATIC ARTHRITIS Narainraj Kamalaraj

73 PERSISTENCE OF BIOLOGICS IN TEATMENT OF PSORIATIS ARTHRITIS PATIENTS – THE FIRST DATA FROM MOSCOW UNIFIED REGISTER OF ARTHRITIS (MUAR)

Ekaterina Koltsova

74 TOTAL KNEE ARTHROPLASTY (TKA) IN A PATIENT WITH MALIGNANT RHEUMATOID ARTHRITIS AND SCHIZOPHRENIA: A CASE REPORT Akiko Sato

75 COMBINATION EFFECT OF EXERCISE INSTRUCTION AND BIOLOGICS ON RHEUMATOID ARTHRITIS PATIENTS. ‐A RANDOMIZED CONTROLLED TRIAL-

Kaori Yoshida

76 SUCCESSFUL TREATMENT WITH RIVAROXABAN FOR PAGET-SCHROETTER SYNDROME MASQUERADING AS THE RELAPSE OF RHEUMATOID ARTHRITIS

Yoichiro Akiyama

78 PREVALENCE AND PATIENT ATTITUDES TOWARDS SIDE EFFECTS OF LOW-DOSE CORTICOSTEROIDS IN THE TREATMENT OF RHEUMATOID ARTHRITIS

Angie Chen

79 THE PATIENT ACCEPTABLE SYMPTOM STATE (PASS) IN ASIAN RHEUMATOID ARTHRITIS (RA) PATIENTS Peter Cheung

80 METABOLIC SYNDROME IN RHEUMATOID ARTHRITIS PATIENT VISITING TERTIARY CARE HOSPITAL, RHEUMATOLOGY CLINIC AT JPMC, KARACHI, PAKISTAN

Sana Shaikh

81 PREVALENCE OF CORONARY ARTERY DISEASE IN A COHORT OF SRI LANKAN PATIENTS WITH RHEUMATOID ARTHRITIS Chathurika Dandeniya

82 CONSOLIDATIONS IN THE LUNG AND MEDIASTINAL LYMPHADENOPATHY OCCUR PREDOMINANTLY IN EARLY ANTI-CITRULLINATED PROTEIN ANTIBODY-POSITIVE PATIENTS WITH RHEUMATOID ARTHRITIS

Yushiro Endo

83 FACTORS FOR DEVELOPMENT OF CONNECTIVE TISSUE DISEASE IN IDIOPATHIC PULMONARY FIBROSIS Byeongzu Ghang

84 BDMARDS REDUCE OSTEOPOROSIS BY SUPRESSING INFLAMMATION AND DISEASE ACTIVITY THROUGH INCREASING BONE FORMATION MARKERS AND REDUCING BONE RESORPTION MARKERS.

Andrisha Inderjeeth

85 WHAT AFFECTS FUNCTIONAL DISABILITY OF THE ELBOW JOINT IN RHEUMATOID ARTHRITIS? Hiromu Ito86 DRY EYE IN INDIAN RHEUMATOID ARTHRITIS PATIENTS AND ASSOCIATION OF DRY EYE WITH DISEASE ACTIVITY. Vaijayanti Joshi

88 DEMOGRAPHICS AND RESPONSE TO TREATMENT OF RHEUMATOID ARTHRITIS PATIENTS TO SYNTHETIC AND BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN MAKATI MEDICAL CENTER

Jennifer Borja-Dimal

89 AN AUDIT ON CLINICAL USE OF HYDROXYCHLOROQUINE (HCQ) AND CURRENT PRACTICE OF SCREENING FOR HCQ RETINOPATHY. Kalum Deshapriya

90 SOCIOECONOMIC DIFFERENCES IN OPIOID USE BY PEOPLE WITH INFLAMMATORY ARTHRITIS: DATA FROM THE AUSTRALIAN RHEUMATOLOGY ASSOCIATION DATABASE (ARAD)

Ashley Fletcher

91 UPADACITINIB IMPACT ON INDIVIDUAL/COMPOSITE DISEASE MEASURES IN RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC OR BIOLOGIC DMARDS

Stephen Hall

92 REMISSION RATE IN PAKISTANI RHEUMATOID PATIENTS: WHERE DO WE STAND? Haseeb Khan

93 EFFICACY OF BARICITINIB COMPARED WITH ADALIMUMAB AND PLACEBO IN PATIENTS WITH RHEUMATOID ARTHRITIS: POST-HOC ANALYSES FROM RA-BEAM AND RA-BEYOND TRIALS

Peter Nash

94 BIFIDOBACTERIUM BIFIDUM ATT ATTENUATES AUTOIMMUNE ARTHRITIS BY REGULATION OF TH17 AND TREG BALANCE. Sung-Hwan Park

95 TREATMENT PATTERNS OF DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS, DRUG SURVIVAL AND FACTORS IN INITIATING BIOLOGICS IN RHEUMATOID ARTHRITIS

Lydia Say Lee Pok

96 A PHASE 3, RANDOMIZED CONTROLLED TRIAL COMPARING UPADACITINIB MONOTHERAPY TO MTX MONOTHERAPY IN MTX-NAÏVE PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS

M Rischmueller

97 HEPATIC SAFETY IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH BARICITINIB: POST-HOC ANALYSIS FROM CLINICAL STUDIES

Evange Romas

98 EFFICACY AND SAFETY OF TOFACITINIB WITH AND WITHOUT METHOTREXATE AND ADALIMUMAB WITH METHOTREXATE IN RHEUMATOID ARTHRITIS BY BASELINE METHOTREXATE DOSE

Tsutomu Takeuchi

99 UPADACITINIB AS MONOTHERAPY: PHASE 3 RANDOMIZED CONTROLLED DOUBLE-BLIND STUDY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE

Yoshiya Tanaka

100 PATIENT-REPORTED OUTCOMES FROM A PHASE 3 STUDY OF BARICITINIB VERSUS PLACEBO IN RHEUMATOID ARTHRITIS PATIENTS: CHINESE SUBPOPULATION ANALYSIS IN RA-BALANCE

Hanjun Wu

101 SCLERODERMA IN CAIRNS: AN EPIDEMIOLOGICAL STUDY. Samuel Abbot102 QTC INTERVAL PROLONGATION AND ITS CORRELATIONS WITH SKIN SCORE IN SYSTEMIC SCLEROSIS Nafiseh Abdolahi103 ECHOCARDIOGRAPHIC ASSESSMENT OF ASYMPTOMATIC CARDIAC INVOLVEMENT IN PATIENTS WITH DIFFUSE SYSTEMIC SCLEROSIS Zahid Alam





104 CLINICAL AND HISTOLOGICAL FEATURES OF NECROTISING MYOPATHY: A PROSPECTIVE SOUTH AUSTRALIAN COHORT STUDY. Jessica Day

105 ANTIFIBROSIS AND ANTI INFLAMMATORY EFFECT OF PHYSALIS ANGULATA EXTRACT IN SCLERODERMA PATIENTS (A DOUBLE BLIND RANDOMIZED CONTROLLED TRIAL)

Sumartini Dewi

106 CORRELATION BETWEEN C-REACTIVE PROTEIN WITH MODIFIED RODNAN’S SKIN SCORE AND N-TERMINAL PROPEPTIDE OF TYPE 1 COLLAGEN IN SCLERODERMA

Sumartini Dewi

108 PREVALENCE AND CLINICAL ASSOCIATION OF THE PRESENCE OF ANTI-NEUTROPHILIC CYTOPLASMIC ANTIBODY IN SYSTEMIC SCLEROSIS: A REVIEW OF THE LITERATURE

Chingching Foocharoen

109 PREVALENCE AND PREDICTORS OF PROTON PUMP INHIBITOR PARTIAL RESPONSE IN GASTROESOPHAGEAL REFLUX DISEASE IN SYSTEMIC SCLEROSIS: AN OPEN LABEL STUDY

Chingching Foocharoen

110 PATIENTS’ EXPERIENCE OF SHOULDER DISORDERS: A SYSTEMATIC REVIEW AND THEMATIC SYNTHESIS OF QUALITATIVE STUDIES Rachelle Buchbinder

111 CLINICAL PREDICTORS OF DISEASE RELAPSE AND MORTALITY IN IMMUNOGLOBULIN G4-RELATED DISEASE FROM A RETROSPECTIVE COHORT IN HONG KONG.

Ho Yin Chung

112 THE RESTORATION OF CELLULAR PROLIFERATION AND CHARACTERISTICS OF HUMAN TENOCYTES BY VITAMIN D Kyunghoon Min

113 SIX MONTHS RESULTS OF TOFACITINIB VERSUS LOWER DOSAGE ETANERCEPT IN PATIENTS WITH REFRACTORY SPONDYLOARTHRITIS; A STUDY FROM BANGLADESH

Nira Ferdous

114 CERTOLIZUMAB PEGOL VERSUS STANDARD CARE IN TREATING NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: RESULTS FOR ASIA-PACIFIC VERSUS REST OF THE WORLD FROM C-AXSPAND

Stephen Hall

115 EFFICACY AND SAFETY OF SECUKINUMAB IN JAPANESE PATIENTS WITH ANKYLOSING SPONDYLITIS: 52 WEEK RESULTS FROM MEASURE 2-J

Mitsumasa Kishimoto

116 CHANGES IN THE LEVEL OF CYTOKINES IN SYNOVIAL FLUID AFFECTED BY DRUGS IN PATIENTS WITH ANKYLOSING SPONDYLITIS Bon San Koo

117 EFFICACY OUTCOMES IN CERTOLIZUMAB PEGOL-TREATED PATIENTS WITH AXIAL SPONDYLOARTHRITIS IN ASIA: RESULTS FROM PART A OF C-OPTIMISE

Robert Landewé

118 REMISSION IN SPONDYLOARTHRITIS- 2 YEAR PROSPECTIVE STUDY IN A TEACHING HOSPITAL, SOUTH INDIA Abirami Manivannan119 PULMONARY SARCOIDOSIS OCCURRING DURING GOLIMUMAB TREATMENT FOR ANKYLOSING SPONDYLITIS Khai Jing Ng

120 REAL WORLD EXPERIENCE WITH INFLIXIMAB BIOSIMILAR (BOW015®) IN ANKYLOSING SPONDYLITIS – A SUB-GROUP ANALYSIS OF THE EAST INDIA COHORT

Jyoti Ranjan Parida

122 CHARACTERIZATION OF THE ROLE OF INCRNAS IN REGULATION OF ANKYLOSING SPONDYLITIS PATHOGENESIS Hui-Chun Yu

123 GLUCOCORTICOIDS AND DAMAGE ACCRUAL IN A COHORT OF LUPUS PATIENTS WITH NO CLINICAL OR SEROLOGICAL DISEASE ACTIVITY

Diane Apostolopoulos

124 PREGNANCY OUTCOMES IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN A TERTIARY CARE HOSPITAL OF DHAKA, BANGLADESH

Rowsan Ara

125 ANTI-SM ANTIBODY DIRECTLY DECREASES TIGHT JUNCTION PROTEIN COMPOSING BLOOD BRAIN BARRIER ON BRAIN ENDOTHELIAL CELLS BY MMP-2 ACTIVATION

Yoshiyuki Arinuma

126 REFRACTORY THROMBOTIC THROMBOCYTOPENIC PURPURA IN A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A CASE REPORT Carlo Antonio Boado128 GOOD RESPONSE TO METHYLPREDNISOLONE PULSE THERAPY AMONG SLE PATIENTS PRESENTING WITH PSYCHOSIS Eunice Victoria Co129 SEVERE TUBERCULOSIS INFECTION FOLLOWING HIGH DOSE STEROID TREATMENT IN SLE: A CASE REPORT Inah Jane Coronel135 TREAT TO TARGET IN SLE - PROSPECTIVE VALIDATION OF THE LUPUS LOW DISEASE ACTIVITY STATE ENDPOINT Vera Golder136 CLINICAL AND IMMUNOLOGICAL MANIFESTATION IN 62 SLE PATIENTS IN NEPAL Arun Gupta

137 MYCOBACTERIAL INFECTION AND ACETYLATOR STATUS AMONG SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS IN TUBERCULOSIS ENDEMIC AREA IN INDONESIA

Laniyati Hamijoyo

138 CLASS TRANSFORMATION IN CLASS V LUPUS NEPHRITIS: INCREASED RISK IN PATIENTS WITH TUBULOINTERSTITIAL INFLAMMATION Seokchan Hong139 TUBULOINTERSTITIAL DAMAGE IN LUPUS NEPHRITIS: FACTORS ASSOCIATED WITH DETERIORATION Seokchan Hong

140 IDENTIFYING SECONDARY FIBROMYALGIA IN SYSTEMIC LUPUS ERYTHEMATOSUS USING PATIENT REPORTED OUTCOMES Frank Huang Sean O’Neill

141 REPRODUCTIVE HEALTH IN SLE Nibha Jain142 CONNECTIVE TISSUE DISEASES WITH RARE ASSOCIATIONS: NIGHTMARE FOR RHEUMATOLOGISTS Vaijayanti Joshi





Wednesday 10 AprilPoster Paper title Presenting Author

1 A CASE OF IGG4 RELATED DISEASE WITH VASCULITIS Ki Won Moon2 A CASE REPORT ON ANTIPHOSPHOLIPID ANTIBODY SYNDROME: FIRST BABY AFTER 4 PREGNANCY LOSS WITH THROMBOCYTOPENIA Fahid Bin. Nazrul

3 PNEUMOCYSTIS JIROVECI PNEUMONIA IN RHEUMATOID ARTHRITIS PATIENT TREATED WITH METHOTREXATE BUT WITHOUT PREDNISOLONE: A CASE REPORT

Jungwon Noh

4 NOVEL MULTIPLE HETEROZYGOUS NUDT15 VARIANTS CAUSED AN AZATHIOPURINE-INDUCED SEVERE ALOPECIA, TONGUE ULCER AND LEUKOPENIA IN A SYSTEMIC LUPUS ERYTHEMATOSUS PATIENT

Mizuna Otsuka

5 SYSTEMIC LUPUS ERYTHEMATOSUS PRESENTING AS BILATERAL SENSORINEURAL HEARING LOSS AND UVEITIS IN AN ELDERLY MALE Grace Penserga6 SIGNIFICANT RESPONSE TO IMMUNOMODULATORY COMBINATION THERAPY FOR RECURRENT KIMURA’S DISEASE: A CASE REPORT Yen-Ju Shih

7 AWARENESS OF DRUG TERATOGENICITY AND CONTRACEPTION USE BY PATIENTS WITH RHEUMATIC DISEASES PRESENTING IN A TERTIARY CARE CENTER OF PAKISTAN

Babur Salim

8 REAL LIFE EXPERIENCES ON PRACTICES OF SOFT TISSUE INFILTRATIONS AND INTRA-ARTICULAR INJECTIONS Kar Hoo Lee9 OPIOID BURDEN IS REDUCED IN LOWER BACK PAIN INPATIENTS ADMITTED UNDER RHEUMATOLOGY, BUT NOT GENERAL MEDICINE Bonnia Liu10 A TRIAL OF SUPRASCAPULAR NERVE BLOCK FOR SHOULDER PAIN IN MOTOR NEURON DISEASE E. Michael Shanahan

11 EXPLORING THE USE AND UPTAKE OF NON-PHARMACOLOGICAL METHODS FOR CHRONIC PAIN MANAGEMENT: FROM A PATIENT AND CLINICIAN PERSPECTIVE

Benjamin Sutu

12 DEFINING THE IMPACT OF TOPICAL NSAIDS ON RENAL FUNCTION, A SURVEY OF AUSTRALASIAN RENAL AND RHEUMATOLOGY SPECIALISTS

Matthew Terrill

13 THE IMPACT OF TOPICAL NSAIDS ON RENAL FUNCTION: A REVIEW OF THE LITERATURE Matthew Terrill

14 MITOCHONDRIAL REACTIVE OXYGEN SPECIES INDUCED BY NADPH OXIDASE 2 DEFICIENCY ENHANCES TH1/TH17 IMMUNE RESPONSES THROUGH SHP1/JAK/STAT SIGNALING

Mingyo Kim

15 SYNOVIAL FLUID PROTEOMICS IN INFLAMMATORY ARTHRITIDES Sang-Hyon Kim

16 LIPOSOMES ENCAPSULATING CALCITRIOL AND ANTIGENIC PEPTIDE MODULATE DENDRITIC CELLS TO EXPAND ANTIGEN-SPECIFIC REGULATORY T-CELLS IN VIVO AND EX VIVO

Xiao Liu

17 SYNERGISTIC ENHANCEMENT OF IL-6 PRODUCTION BY HUMAN PERIPHERAL BLOOD MONOCYTES BY ANTI-SM AND ANTI-RNP ANTIBODIES

Yu Matsueda

18 VITAMIN D SUPPLEMENTATION IMPROVES DISEASE SEVERITY, SUPPRESSES INTERFERON-Α IN SLE: A LONGITUDINAL STUDY Satarupa Mohapatra

19 HUMAN MESENCHYMAL STEM CELLS INDUCE THE EXPRESSION OF CD4+ CD25+ FOXP3+ PROGRAMMED CELL DEATH-1+ REGULATORY T CELLS

Chin Hee Mun

20 SERUM PROLIDASE- A NOVEL BIOMARKER OF ANKYLOSING SPONDYLITIS Jayakrishna Niari

21 ABERRANT ANGIOGENESIS IS MEDIATED BY CONNECTIVE TISSUE GROWTH FACTOR THROUGH NOTCH-1 ACTIVATION IN PATIENTS WITH RHEUMATOID ARTHRITIS

Kazuhisa Nozawa

27 TRANSLATION OF REVISED WHO-ILAR-COPCORD CORE ENGLISH QUESTIONNAIRE INTO BANGLA AND ITS CROSS-CULTURAL ADAPTATION AND VALIDATION

Shamim Ahmed

28 LAG TIME BETWEEN ONSET OF SYMPTOMS AND INITIATION OF DMARD FOR RHEUMATOID ARTHRITIS PATIENTS AND FACTORS RESPONSIBLE FOR THE DELAY

Zahid Amin

29 RISK FACTORS OF CMV INFECTION IN PATIENTS WITH AUTOIMMUNE DISEASES IN A SOUTH-EAST ASIAN POPULATION IN SINGAPORE Stanley Angkodjojo

30 PREVALENCE OF RHEUMATIC IMMUNE RELATED ADVERSE EVENTS (RIRAE) IN PATIENTS WITH METASTATIC MELANOMA TREATED WITH IMMUNOTHERAPY: PRELIMINARY RESULTS

Alana Bruce

31 THYROID DYSFUNCTION IN CONNECTIVE TISSUE DISORDER PRESENTING AT RHEUMATOLOGY CLINIC AT JPMC, KARACHI, PAKISTAN Sana Sheikh32 PSYCHOSOCIAL BURDEN OF RHEUMATIC DISEASE IN ADOLESCENTS & YOUNG ADULTS Mariya Hamid

33 AUSTRALIAN PATIENT PREFERENCES FOR TARGETED SYNTHETIC AND BIOLOGIC DISEASE MODIFYING ANTIRHEUMATIC DRUGS: A DISCRETE CHOICE EXPERIMENT

Gabor Hutas

34 TRANSLATION, CROSS-CULTURAL ADAPTATION AND VALIDATION OF SHORT-FORM PATIENT SATISFACTION QUESTIONNAIRE (PSQ-18) INTO BENGALI

Nazrul Islam

35 NUTRITIONAL STATUS IN PATIENTS WITH RHEUMATIC DISEASES; A STUDY FROM BANGLADESH Sifat Jahan36 BURDEN OF DISEASE IN A NATIONAL SAMPLE OF WOMEN IN CHILDBEARING YEARS WITH RHEUMATIC DISEASES IN KOREA Jisoo Lee

37 WILLINGNESS TO AVAIL OF PRIVATE OUTPATIENT MUSCULOSKELETAL HEALTH AND WELLNESS SERVICES AMONG ELDERLY IN AN URBANIZED CITY IN MANILA, PHILIPPINES

Elizabeth Manlulu

38 THE AUSTRALIAN ARTHRITIS & AUTOIMMUNE BIOBANK COLLABORATIVE (A3BC) & THE AUSTRALIAN RHEUMATOLOGY ASSOCIATION DATABASE (ARAD)

Lyn March

39 A PATIENT WITH LIMBIC ENCEPHALITIS, EAR PERICHONDRITIS AND EPISCLERITIS - AN UNUSUAL PRESENTATION OF RELAPSING POLYCHONDRITIS

Stanley Angkodjojo

40 ASSESSMENT OF EPIDEMIOLOGY, SYMPTOMS, ACCURACY OF DIAGNOSTIC EXAMINATION METHODS AND X RAYS USED FOR YOUNG PATIENTS WITH PATELLA FEMORAL SYNDROME

H Savidya Dhanushka Appuhamy

41 HOW COMMON IS IMAGING FOR LOW BACK PAIN? A SYSTEMATIC REVIEW AND META-ANALYSIS Aron Downie42 AN UNUSUAL CAUSE OF KNEE SWELLING Quake Ct

43 PATTERNS OF MUSCLE OEDEMA, ATROPHY AND FATTY REPLACEMENT IN THE IDIOPATHIC INFLAMMATORY MYOPATHIES: A RETROSPECTIVE ANALYSIS OF MAGNETIC RESONANCE IMAGING

Jessica Day

44 UTILIZATION AND IMPACT OF MUSCULOSKELETAL ULTRASONOGRAPHY ON RHEUMATOID ARTHRITIS PATIENTS IN CLINICAL PRACTICE Liu Hong Eow Nor Shuhaila Shahril

45 CLINICAL UTILITY OF ULTRASONOGRAPHY IN DIAGNOSING AND MONITORING DISEASE ACTIVITY OF RELAPSING POLYCHONDRITIS Satoshi Inotani

46 DETECTING HAND JOINT SUBLUXATION IN RADIOGRAPHIC IMAGES USING DEEP LEARNING: TOWARD THE DEVELOPMENT OF AUTOMATIC EVALUATING SYSTEM FOR BONE DESTRUCTION

Keisuke Izumi

48 SAFETY OF ARTHROCENTESIS IN PATIENTS RECEIVING THERAPEUTIC ANTICOAGULATION WITH WARFARIN AND DIRECT ORAL ANTICOAGULANTS – A RETROSPECTIVE STUDY

Mueed Mian

49 FOREFOOT SYNOVITIS SHOULD BE EVALUATED INDEPENDENTLY OF GLOBAL ASSESSMENT OF DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS

Hiroto Nishimura

50 PRELIMINARY VALIDATION OF SHEAR WAVE ELASTOGRAPHY IN THE DIAGNOSTIC EVALUATION OF MUSCLE DISEASE Shereen Paramalingam

51 18F-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY/ MAGNETIC RESONANCE IMAGING (18F-FDG PET/MRI) CORRELATED WITH THE HISTOLOGIC SCORING SYSTEM IN C PROTEIN-INDUCED MYOSITIS MODEL

Jeong Yeon Kim

52 THE RELATIONSHIP BETWEEN CLINICAL FINDINGS OF LOW BACK PAIN AND MAGNETIC RESONANCE IMAGING RESULTS Mohsen Soroush54 UNILATERAL SACROILIITIS DUE TO MULTI DRUG RESISTANT STRAIN OF SALMONELLA TYPHI: A REPORT OF TWO CASES Assadullah Dahani55 SYSTEMIC LUPUS ERYTHEMATOSUS IN A PATIENT WITH HIV INFECTION: A DIAGNOSTIC DILEMMA Sp Gan




59 HOSPITAL PRESENTATION WITH INFECTION IN CHILDREN WITH IGA VASCULITIS BEFORE AND AFTER DIAGNOSIS Johannes Nossent60 INFECTION RATES IN ADULT PATIENTS WITH IGA VASCULITIS BEFORE AND AFTER DIAGNOSIS Johannes Nossent61 SEPTIC ARTHRITIS SECONDARY TO STREPTOCOCCUS DYSGALACTIAE SUBSPECIES DYSGALACTIAE BACTEREMIA: A CASE REPORT Jane Suaco62 TUBERCULOSIS INFECTION IN CHINESE PATIENTS WITH GIANT CELL ARTERITIS Yun Zhang63 EFFECTS OF CURCUMIN ON SERUM URIC ACID AND URIC ACID CLEARANCE IN HYPERURICEMIA Pannipa Bupparenoo64 SEASONAL VARIATIONS AND ASSOCIATED FACTORS OF GOUT ATTACKS: A PROSPECTIVE MULTICENTER DATA IN SOUTH KOREA Hyo-Jin Choi

65 P2X7R PROMOTES SECRETION OF IL-1Β IN MACROPHAGES OF RATS WITH ACUTE GOUTY ARTHRITIS BY REGULATING NLRP3 INFLAMMASOME

Xiaojuan Dai

66 EFFECTIVENESS OF FEBUXOSTAT IN THE MANAGEMENT OF GOUT – THE KUALA LUMPUR HOSPITAL EXPERIENCE Syang Pyng Gan

67 CORRELATION BETWEEN HIGHT SENSITIVITY C-REACTIVE PROTEIN LEVELS WITH CAROTID INTIMA MEDIA THICKNESS IN ASYMPTOMATIC HYPERURICEMIA

Rakhma Yanti Hellmi

69 PREDICTIVE FACTORS OF INCREASED VASCULAR STIFFNESS IN PATIENTS WITH GOUT AND HYPERURICEMIA Jinseok Kim

70 ASSOCIATION BETWEEN SMOKING AND SERUM URIC ACID IN KOREAN POPULATION: DATA FROM KOREA NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY 2016

Seong-Kyu Kim

71 GOUT REVISITED: CLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES IN A TERTIARY STATE HOSPITAL Kar Hoo Lee72 HOW MUCH DO PATIENTS KNOW ABOUT GOUT AND ITS TREATMENT? Kar Hoo Lee

73 COHORT OF ALLOPURINOL SEVERE CUTANEOUS ADVERSE REACTION - GENE TESTING MIGHT BE BETTER THAN "GO LOW GO SLOW" STRATEGY

Moon-Ho Alexander Leung

74 EVALUATION OF HIP JOINT DESTRUCTION IN RHEUMATOID ARTHRITIS DURING DIFFERENT PERIOD Koji Suzuki

75 PATIENT PERCEPTION OF PSORIATIC ARTHRITIS TREATMENT AND COMMUNICATION WITH PHYSICIANS IN AUSTRALIA: RESULTS FROM A PATIENT SURVEY

Irwin Lim

76 PATTERN AND PROFILE OF PSORIATIC ARTHRITIS IN A COMMUNITY BASED REFERRAL PRACTICE OVER A DECADE (2007-2017) Abraham Mohan

77 EFFICACY OF IXEKIZUMAB IN DIFFERENT PHENOTYPES OF PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM THE SPIRIT TRIALS

Peter Nash

78 CIRCULATING ADIPOKINES AND PHENOTYPE IN PSORIATIC ARTHRITIS Premarani Sinnathurai79 CIRCULATING ADIPOKINES IN PSORIATIC ARTHRITIS: A SYSTEMATIC REVIEW Premarani Sinnathurai

80 EFFECT OF BIOLOGICS ON RADIOGRAPHIC PROGRESSION OF PERIPHERAL JOINTS IN PATIENTS WITH PSORIATIC ARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS

Dongze Wu

82 ASSESSMENT OF DISEASE-SPECIFIC KNOWLEDGE OF PATIENTS WITH RHEUMATOID ARTHRITIS A. K. M. Kamruzzaman83 EXTRAPULMONARY TUBERCULOSIS IN TWO RHEUMATOID ARTHRITIS CASES DURING TREAT-TO-TARGET THERAPY Hiroshi Kataoka

84 INTERLEUKIN-6 RECEPTOR INHIBITION AND TUMOR NECROSIS FACTOR-ALPHA INHIBITION THERAPIES INCREASED THE BODY WEIGHT OF PATIENTS WITH RHEUMATOID ARTHRITIS

In Ah Choi

85 AUDIT OF ANTIHYPERTENSIVE AND CHOLESTEROL LOWERING THERAPY USAGE IN PATIENTS WITH INFLAMMATORY ARTHRITIS ATTENDING AN INFLAMMATORY ARTHRITIS CLINIC

Ruby Kirupananther

86 CLINICAL PROBLEMS OF ELDERLY ONSET RHEUMATOID ARTHRITIS PATIENTS IN JAPAN Takahiko Kurasawa

87 DEVELOPMENT AND VALIDATION OF PET/CT-BASED TOOL FOR THE EVALUATION OF JOINT COUNTS AND DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS

Sang Jin Lee

88 MILD COGNITIVE IMPAIRMENT IN ELDERLY PATIENTS WITH RHEUMATOID ARTHRITIS Etsuko Maeshima89 THE ASSOCIATED FACTORS FOR FALLS AND FEAR OF FALLS IN INDIAN PATIENTS WITH RHEUMATOID ARTHRITIS Panna Mishra90 IMPACT OF COMORBIDITIES IN PATIENTS WITH RHEUMATOID ARTHRITIS: A STUDY FROM A TERTIARY CARE CENTER IN PAKISTAN Noreen Nasir

91 MODIFIED RHEUMATOID ARTHRITIS IMPACT OF DISEASE (RAID) SCORE, A POTENTIAL TOOL FOR DEPRESSION AND ANXIETY SCREENING AMONG RHEUMATOID ARTHRITIS PATIENTS

Khai Jing Ng

93 COMPARATIVE EFFECTIVENESS OF BIOLOGIC DMARDS AND JAK INHIBITORS IN PATIENTS WITH AN INADEQUATE RESPONSE TO TNF INHIBITORS: A NETWORK META-ANALYSIS

Tsang Tommy Cheung

94 EXPERIENCE WITH LOW-DOSE RITUXIMAB IN RHEUMATOID ARTHRITIS IN A DISTRICT GENERAL HOSPITAL OF SRI LANKA Uthpala Dissanayake Mudiyanselage

95 MAINTENANCE OF LOW DISEASE ACTIVITY AFTER STOPPING CONCOMITANT METHOTREXATE DURING TOCILIZUMAB TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS (T-REX STUDY)

Masahiro Hanabayashi

96 A CASE OF EXAMINING THE ASSOCIATION OF PAIN TRANSITION AND MUSCULOSKELETAL ULTRASOUND FINDINGS AFTER ORAL ADMINISTRATION OF JAK INHIBITOR

Hiroki Ikai

97 USE OF TOFACITINIB (TOFA) IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) IN MOSCOW. ANALYSIS DATA FROM MOSCOW UNIFIED ARTHRITIS REGISTRY (MUAR)

Ekaterina Koltsova

99 EFFECT OF SARILUMAB ON GLYCOSYLATED HEMOGLOBIN IN PATIENTS WITH RHEUMATOID ARTHRITIS AND DIABETES Hubert Van Hoogstraten

100 LONG-TERM EFFECT OF SARILUMAB PLUS METHOTREXATE ON DISEASE ACTIVITY, PHYSICAL FUNCTION AND RADIOGRAPHIC PROGRESSION: A 5-YEAR ANALYSIS

Hubert Van Hoogstraten

101 PATIENTS SWITCHED TO SARILUMAB FROM ADALIMUMAB ACHIEVE CLINICALLY IMPORTANT IMPROVEMENTS IN DISEASE ACTIVITY: RESULTS FROM MONARCH TRIAL OPEN-LABEL EXTENSION

Hubert Van Hoogstraten

102 A RETROSPECTIVE ANALYSIS ON RITUXIMAB FOR RA AFTER THREE YEARS - AT A DOSE OF 500MG Geetha Wickrematilake

103 PREVALENCE OF RESTRICTIVE LUNG DISEASE IN SYSTEMIC SCLEROSIS PATIENTS IN RHEUMATOLOGY OUTPATIENT CLINIC IN CIPTO MANGUNKUSUMO GENERAL HOSPITAL

Andi Ginting

104 ROLE OF ULTRASOUND IN SKIN AND END-ORGAN DISEASE IN SCLERODERMA Pauline Habib

105 TRABECULAR BONE SCORE IN THAI SYSTEMIC SCLEROSIS PATIENTS: IS IT A BETTER TOOL FOR PREDICTING FRACTURES? Nipaporn Intarasattakul

106 CLINICAL CONSTELLATION OF ANTI-RNP POSITIVE PATIENTS IN KOREA Mi Il Kang107 SCLERODERMA RENAL CRISIS: OBSERVATIONS FROM THE SOUTH AUSTRALIAN SCLERODERMA REGISTER (SASR) Yassmin Khadra108 A RARE CASE OF ADULT ONSET STILLS DISEASE WITH DERMATOMYOSITIS: A DIAGNOSTIC CHALLENGE Furqan Khan

110 ANTI-PL-7 ANTIBODY-POSITIVE DERMATOMYOSITIS COMPLICATED WITH RAPID PROGRESSIVE INTERSTITIAL LUNG DISEASE AND COLON CANCER SUCCESSFULLY UNDERWENT LAPAROSCOPIC COLECTOMY AFTER TRIPLE-IMMUNOSUPPRESSIVE THERAPY

Taiga Kuga

111 DISCREPANCIES IN CLINICAL CHARACTERISTICS BETWEEN CANCER- AND NON-CANCER ASSOCIATED ANTI-MELANOMA DIFFERENTITATION-ASSOCIATED GENE 5-ASSOCIATED DERMATOMYOSITIS IN A THAI UNIVERSITY HOSPITAL

Sasipa Muennuch

112 AUDIT OF THE MANAGEMENT OF DIGITAL ULCERS SECONDARY TO RAYNAUD’S PHENOMENON IN PATIENTS WITH SCLERODERMA AT FIONA STANLEY HOSPITAL

Debbie Olsson-White






113 INFLUENCE OF RF AND HLA B27 OF CLINICAL PHENOTYPE ON RA-SSA OVERLAP: A RETROSPECTIVE CROSS SECTIONAL STUDY Kiran Adam

114 ACCURACY AND RELIABILITY OF SPINAL INFLAMMATION INTENSITY ON STIR SEQUENCE ACCORDING TO THE SPARCC MRI INDEX IN AXIAL SPONDYLOARTHRITIS

Ho Yin Chung

115 CORRELATING ASDAS AND BASDAI IN ANKYLOSING SPONDYLITIS Nibha Jain116 SERUM MIR-214 AS A NONINVASIVE BIOMARKER FOR ANKYLOSING SPONDYLITIS Tae-Jong Kim

117 REMISSION OF PARADOXICAL SKIN LESIONS BY TRIPTERYGIUM WILFORDII HOOK F TREATMENT IN SAPHO SYNDROME: A CASE REPORT

Qi Lei

118 INTERESTING CASE OF ANKYLOSING SPONDYLITIS WITH SCLERODERMA OVERLAP Swetal Pandey119 PREVALENCE OF AND FACTORS ASSOCIATED WITH SARCOPENIA IN PATIENTS OF ANKYLOSING SPONDYLITIS Ran Song120 A SYSTEMATIC REVIEW OF APPS FOR PATIENTS WITH SPONDYLOARTHRITIS TO MONITOR THEIR DISEASE ACTIVITY Charmaine Wang

121 MORTALITY IN AUTOIMMUNE RHEUMATIC DISEASES WITH ANTI-RO/SSA ANTIBODY IN KOREA: SINGLE CENTER-BASED RETROSPECTIVE STUDY

Seong-Kyu Kim

122 INCREASED POSSIBILITY OF ANTIPHOSPHOLIPID SYNDROME IN PSEUDO-PSEUDO MEIGS SYNDROME Seong-Ryul Kwon123 SLE PATIENTS WITH CEREBRAL LUPUS IN A MALAYSIAN RHEUMATOLOGY CENTRE Lau Ing Soo124 NATIONAL DATA BASED ANALYSIS OF MALIGNANCY IN KOREAN SJOGREN’S SYNDROME PATIENTS Chan Hee Lee

125 ASSESSMENT OF A MULTIPLEX AUTOANTIBODY TEST, SLE-KEY®, TO RULE OUT SYSTEMIC LUPUS ERYTHEMATOSUS IN CHINESE SUBJECTS

Peter Lipsky

127 ANTI-C1Q ANTIBODIES IN MALAYSIA’S LUPUS NEPHRITIS AND NON-LUPUS NEPHRITIS PATIENTS: A SINGLE CENTRE EXPERIENCE Mohd Shahrir Mohamed Said

129 EFFECT OF THE METABOLIC SYNDROME ON INCIDENT VASCULAR EVENTS AND MORTALITY IN FOUR RHEUMATIC DISEASES: AN 8-YEAR LONGITUDINAL ANALYSIS

Chi Chiu Mok

130 CLINICAL FEATURES AND RISK FACTORS FOR MORTALITY AMONG PAKISTANI PATIENTS WITH SLE Noreen Nasir132 THE IMPORTANCE OF TUBULORETICULAR INCLUSION BODIES IN LUPUS NEPHRITIS Johannes Nossent133 SOLUBLE SIGLEC-5 IS A NOVEL SALIVARY BIOMARKER FOR PRIMARY SJOGREN’S SYNDROME Minae Oh

134 MULTIDIMENSIONAL HEALTH ASSESSMENT QUESTIONNAIRE IN SYSTEMIC LUPUS ERYTHEMATOSUS: COMPARISON WITH THE SHORT FORM 36 VERSION 2

Sean O'Neill

136 CYTOKINES AND HEALTH-RELATED QUALITY OF LIFE IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) Warren Raymond

137 PRINCIPAL COMPONENT ANALYSIS REVEALS DISCONNECT BETWEEN REGULATORY CYTOKINES AND DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS

Warren Raymond

138 COGNITIVE FUNCTION WAS NOT CORRELATED WITH DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS Aep Saepudin139 LESS FATIGUE IN LUPUS LOW DISEASE ACTIVITY STATE (LLDAS) Ryan Saputra

140 CLINICAL SIGNIFICANCE OF ANTIPHOSPHOLIPID ANTIBODIES (APL) AMONG MALAYSIAN SYSTEMIC LUPUS ERYTHEMATOSUS Syahrul Sazliyana Shaharir

141 COMPARISONS OF CLINICAL MANIFESTATIONS AND PROGNOSIS BETWEEN GIANT CELL ARTERITIS PATIENTS WITH OR WITHOUT SENSORINEURAL HEARING LOSS: A RETROSPECTIVE STUDY

Xiaotian Chu

142 MYOSITIS AS THE PRESENTING FEATURE OF ANCA-ASSOCIATED VASCULITIS: A LOCAL EXPERIENCE AND LITERATURE REVIEW Thilinie De Silva

143 CYTOMEGALOVIRUS COLITIS (CMV) FOLLOWING CYCLOPHOSPHAMIDE THERAPY IN A PATIENT WITH POLYARTERITIS NODOSA (PAN) Anna Farazilah Mohd Salleh

144 SYSTEMIC VASCULITIS IN A PATIENT WITH PRIMARY BILIARY CIRRHOSIS: LESSONS FROM A CASE REPORT Mooikhin Hng145 MORTALITY IN THAI PATIENTS WITH ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODIES (ANCA)-ASSOCIATED VASCULITIS Porntip Intapiboon

146 SUBCUTANEOUS TOCILIZUMAB IN REFRACTORY GIANT CELL ARTERITIS: A CASE REPORT Haseeb Khan, Nighat Mir Ahmed

147 UTILIZING COMBINED PULSED DYE AND ND:YAG LASER IN THE TREATMENT OF CONNECTIVE TISSUE DISEASES: CASE SERIES Hyun-Sook Kim




Thursday 11 AprilPoster Paper title Presenting Author

1 NONRADIOGRAPHIC SPONDYLOARTHRITIS: A CASE REPORT OF A FILIPINO FEMALE PRESENTING WITH CHRONIC INFLAMMATORY BACK PAIN

Hanna Monica Sollano

2 SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PRESENTING WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) Molly Thabah3 CASE REPORT OF A PATIENT WITH REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS: WHEN RITUXIMAB IS ORGAN SAVING Ashik Uz Zaman6 THE CORRELATIONS OF COPING STYLE AND SOCIAL SUPPORT IN CHINESE PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS Biyu Shen7 HISTOPATHOLOGICAL CHANGES OF SYNOVIAL TISSUE IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TNF INHIBITORS Yoshinori Takashima

9 CORRELATION BETWEEN B-CELL ACTIVATING FACTOR (BAFF) LEVELS AND DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENT IN HASAN SADIKIN GENERAL HOSPITAL

Ria Vitri

10 FUNDAMENTAL DIFFERENCE IN MACROPHAGE BETWEEN GIANT CELL ARTERITIS AND CORONARY ARTERY DISEASE Ryu Watanabe

11 ARTHITOGENIC CLONALLY-EXPANDED AUTOANTIGEN-SPECIFIC CD4+ T CELLS ARE A TARGET FOR PREVENTION OF AUTOIMMUNE ARTHRITIS

Pascale Wehr

12 DNA METHYLATION IS DISTINCT BETWEEN AS CASES AND CONTROLS AND IN DIFFERENT PERIPHERAL BLOOD MONONUCLEAR CELL TYPES

Jessica Whyte

13 PRE-CLINICAL EVALUATION OF NINTEDANIB FOR CONNECTIVE TISSUE DISEASES WITH COMORBID PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE OR OTHER ORGAN MANIFESTATIONS

Lutz Wollin

14 4-PHENYLBUTYRIC ACID AMELIORATES LUPUS HEPATITIS AND NEPHRITIS THROUGH SUPPRESSION OF NF-KB ACTIVATION IN EXPERIMENTAL LUPUS MODEL

Wan-Hee Yoo Yoo

17 VITAMIN D PROTECTS PODOCYTES FROM AUTOANTIBODIES INDUCED INJURY IN LUPUS NEPHRITIS BY REDUCING ABERRANT AUTOPHAGY

Zhaohui Zheng

18 THE ROLE OF LOW SOCIO-ECONOMIC STATUS, EDUCATION AND OCCUPATION IN PATIENTS WITH RHEUMATOID ARTHRITIS Panna Mishra

19 RELATIONSHIP BETWEEN BMI AND QUALITY OF LIFE OF WITH THE SEVERITY DISEASES ACTIVITY IN PEOPLE WITH RHEUMATOID ARTHRITIS

Nasrin Moghimy

20 HOW URGENT IS THE ISSUE? TRIAGE IN A BUSY PUBLIC RHEUMATOLOGY CLINIC Joel Riley21 ASSOCIATION OF DIETARY AND NUTRIENT PATTERNS WITH OSTEOARTHRITIS AMONG AUSTRALIAN ADULTS Carlee Ruediger22 WHAT IS AN ‘OPTIMAL’ SPINAL POSITION DURING SLEEP? A SYSTEMATIC REVIEW Julia Sewell23 NEW ONSET ACUTE INFLAMMATORY ARTHRITIS IN HOSPITALIZED PATIENTS Young Sun Suh

24 BEYOND THE CONSULTATION: THE VALUE OF PERSONALISED HANDWRITTEN PATIENT SUMMARIES IN A RURAL RHEUMATOLOGY PRACTICE

Olav Tvedten

25 THE OMERACT CORE DOMAIN SET FOR CLINICAL TRIALS OF SHOULDER DISORDERS Samuel Whittle26 BURDEN OF MUSCULOSKELETAL DISORDERS IN CHINA, 1990–2016: FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY 2016 Dongze Wu28 CLINICAL AUDIT OF MALIGNANCIES AMONG PATIENTS WITH CHRONIC RHEUMATIC DISEASES IN HOSPITAL MELAKA (MALAYSIA) Yew Jasmine29 PREPARATION AND BIOLOGICAL EFFECTS OF IGURATIMOD NANOSCALE SUSTAINED RELEASE SYSTEM Jinxia Zhao

30 FILARIASIS IS THE COMMONEST CAUSE OF MUSCULOSKELETAL SYMPTOMS IN EASTERN INDIA: A SINGLE CENTRE PROSPECTIVE STUDY

Sarita Behera

32 NEUROINFLAMMATION IN FIBROMYALGIA ASSESSED BY PROTON MAGNETIC RESONANCE SPECTROSCOPY – A PILOT STUDY Richard Kwiatek33 APPLICATION OF A REAL-TIME PAIN MONITORING SYSTEM IN KOREAN FIBROMYALGIA PATIENTS: A PILOT STUDY Minae Oh34 INVESTIGATION OF PATHOLOGY OF NEUROIMMUNE DISORDER SYNDROME (HANS) SEEN AFTER HPV VACCINATION Onishi Takahiro

35 THE PRESCRIBING PATTERN OF ALLOPURINOL IN CURRENT DAILY PRACTICE AT KING CHULALONGKORN MEMORIAL HOSPITAL (KCMH) Theerada Assawasaksakul

36 P2X7R REGULATES THE UPTAKE OF YO-PRO-1 BY MACROPHAGES IN RATS WITH ACUTE GOUTY ARTHRITIS Xiaojuan Dai37 SERUM URIC ACID AND SERUM BILIRUBIN AND THEIR ASSOCIATION IN THAI PATIENTS WITH PARKINSON’S DISEASE Worawit Louthrenoo

38 THE FURY OF GOUT REMAINS UNABATED: A LARGE RETROSPECTIVE COHORT ANALYSIS OF INDIAN PATIENTS MANAGED IN A COMMUNITY RHEUMATOLOGY CENTRE

Bharat Manchanda

39 CROSS SECTIONAL STUDY OF CAROTID INTIMA MEDIA THICKNESS (CIMT) IN GOUTY ARTHRITIS (GA) PATIENTS WITH LOW FRAMINGHAM RISK SCORE

Mohd Shahrir Mohamed Said

40 SURVEY ON THE HEALTHCARE PRACTITIONERS' KNOWLEDGE, PRACTICE AND ILLNESS PERCEPTION IN MANAGING PATIENTS WITH GOUT IN KELANTAN STATE, MALAYSIA

Kiah Loon Ng

41 PROFILE OF VITAMIN D LEVEL AMONG RANDOM COHORT OF PATIENTS, ANALYSIS OF LIMITED DATA FROM A LABORATORY Shahidur Rahman42 2015 ACR/EULAR GOUT CLASSIFICATION CRITERIA: APPLICATION IN VIETNAM Huyen Trang Tran

45 STUDY OF EPIDEMIOLOGY, SYMPTOM VARIABILITY AND KNOWLEDGE ASSESSMENT OF KNEE JOINT OSTEOARTHRITIS PATIENTS IN SRI LANKA

Savidya Appuhamy

46 HIGH BASELINE FAT MASS IS ASSOCIATED WITH HIGH INTENSITY LOW BACK PAIN AND DISABILITY IN COMMUNITY BASED ADULTS Sharmayne Brady

47 TRANSLATING A CLINICAL CARE STANDARD FOR KNEE OSTEOARTHRITIS INTO ROUTINE CLINICAL CARE: A SYSTEMATIC SCOPING REVIEW TO INFORM IMPLEMENTATION PLANNING

Rachelle Buchbinder

48 QUANTIFYING KNEE JOINT EFFUSIONS WITH CLINICAL TESTS, MUSCULOSKELETAL ULTRASOUND AND SYNOVIAL FLUID ASPIRATION: A PROSPECTIVE COHORT STUDY

Thilinie De Silva

49 INAPPROPRIATE USE OF OPIOIDS FOR INCIDENT KNEE AND HIP OSTEOARTHRITIS Martin Englund50 THE EFFECT OF FACE TO FACE EDUCATION ON WEIGHT LOSS OF OVERWEIGHT PATIENTS WITH KNEE OSTEOARTHRITIS Sasan Fallahi52 THE PREVALENCE AND DISTRIBUTION OF FABELLA DETERMINED BY RADIOGRAPHS IN KOREANS Jin-Wuk Hur53 ASSOCIATION OF AGE WITH THE RATE OF CHANGE IN KNEE CARTILAGE VOLUME: A 10.7 YEAR LONGITUDINAL COHORT STUDY Matthew Jiang

54 PRO- AND ANTIOXIDATIVE BALANCE AND OSTEOARTHRITIS IN KOREAN ADULTS: THE KOREA NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (2014–2015)

Kyong-Hee Jung

55 INFLIXIMAB FOR THE TREATMENT OF REFRACTORY KAWASAKI DISEASE IN CHILDREN: A META-ANALYSIS Abigail Melicor56 SCURVY, A DISEASE NOT TO BE FORGOTTEN IN THE 21ST CENTURY Sue Kheng Ng

57 VASO-OCCLUSIVE RETINAL VASCULITIS IN CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS: CLINICAL ASSOCIATIONS AND OUTCOMES

Sue Kheng Ng

58 ACUTE MYELOID LEUKEMIA MIMICKING SYSTEMIC LUPUS ERYTHEMATOSUS IN A FILIPINO FEMALE ADOLESCENT: A CASE REPORT Jacqueline Rapacon59 SYSTEMIC LUPUS ERYTHEMATOSUS IN CHILDREN: A 10-YEAR RETROSPECTIVE ANALYSIS OF MORTALITY AND MORBIDITY Fema Rivera

60 SOUTHERN HEMISPHERE EDUCATIONAL PARTNERSHIP FOR PEDIATRIC ARTHRITIS AND RHEUMATOLOGICAL DISEASES (SHEPPARD): AN INTERNATIONAL EDUCATIONAL PROGRAM

Ricardo Russo





61 A CASE OF JUVENILE DERMATOMYOSITIS (JDM) CALCIFICATION SUCCESSFULLY TREATED WITH ABATACEPT Sukesh Sukumaran

62 SERUM COMPLEMENT REGULATORY PROTEINS PREDICT THE THERAPEUTIC RESPONSE OF CYCLOPHOSPHAMIDE IN PATIENTS WITH LUPUS NEPHRITIS

Kuo-Wei Yeh

63 CEREBROVASCULAR INFARCTION IN AN ADOLESCENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND POSITIVE ANTIPHOSPHOLIPID ANTIBODY: A CASE REPORT

Abigail Yumul

64 TUMOUR NECROSIS FACTOR INHIBITION RESULTS IN WEIGHT GAIN IN PATIENTS WITH INFLAMMATORY ARTHRITIS Andrew Brooks

66 SWITCHING FROM ETANERCEPT IN PATIENTS WITH RHEUMATOID ARTHRITISDATA FROM MOSCOW UNIFIED ARTHRITIS REGISTRY (MUAR)

Ekaterina Koltsova

67 DEMYELINATION AMONGST PATIENTS EXPOSED TO TUMOUR NECROSIS FACTOR-ALPHA INHIBITOR (TNFI): A CASE SERIES Hui Jean Lee

68 EXPRESSION OF ANTIDRUG ANTIBODIES TO ADALIMUMAB MONOTHERAPY HAS NO INFLUENCE ON IMPROVEMENT OF JOINT INFLAMMATION: SUBANALYSIS OF THE CHANGE STUDY

Thomas Mosch

69 BIOSIMILARS IN RHEUMATOLOGY- REAL LIFE EXPERIENCE OVER 3 YEARS Subramanian Nallasivan

70 COMPARISON OF EFFICACY OF FIRST- VERSUS SECOND-LINE GOLIMUMAB IN JAPANESE PATIENTS WITH RHEUMATOID ARTHRITIS Koei Oh

71 IMPACT OF ADALIMUMAB (HUMIRA®) ON HEALTH AND DISABILITY OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS, CROHN’S DISEASE OR PSORIASIS: VITALITY STUDY

David Poppelwell

72 THE PROFILE INVESTIGATING OF RHEUMATOID ARTHRITIS (RA) PATIENTS WHO RECEIVED ADALIMMAB THERAPY IN AORA (AKITA ORTHOPEDIC GROUP ON RA)

Tsutomu Sakuraba

73 RETENTION AND SAFETY OF BIOSIMILAR CT-P13 IN PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM THE KOREAN COLLEGE OF RHEUMATOLOGY BIOLOGICS REGISTRY

Kichul Shin

74 TNFI TREATMENTS FOR WOMEN WITH CHRONIC RHEUMATIC DISEASES: A COMPARISON OF ATTITUDES AND PERCEPTIONS OF CLINICIANS IN AUSTRALIA AND JAPAN

Yoshiya Tanaka

76 ELEVATING THE ROLE OF CARERS IN THE PATIENT JOURNEY CAN POTENTIALLY IMPROVE RA MANAGEMENT Rachel Norager

77 GUT MICROBIOME PROFILING OF RHEUMATOID ARTHRITIS PATIENTS REVEALS A NOVEL BIFIDOBACTERIUM STRAIN FOR DEVELOPMENT OF PHARMABIOTICS

Sung-Hwan Park

78 FATIGUE AND ITS ASSOCIATED FACTORS IN A MULTI-ETHNIC COHORT OF MALAYSIAN RHEUMATOID ARTHRITIS PATIENTS Hwai Jien Lee

81 FOLLOW-UP FREQUENCY IN PATIENTS WITH RHEUMATOID ARTHRITIS AND ITS ASSOCIATION WITH DISEASE ACTIVITY AT A TERTIARY CARE CENTER

Babar Salim

82 GLUCOCORTICOID SPARING EFFECT OF TARGETED THERAPY IN RHEUMATOID ARTHRITIS: REAL-WORLD DATA FROM THE KOREAN COLLEGE RHEUMATOLOGY BIOLOGICS REGISTRY

Eunyoung Emily Lee

83 DISEASE MODIFYING ANTI-RHEUMATIC DRUGS ADHERENCE IN THAI RHEUMATOID ARTHRITIS PATIENTS: THE IMPORTANCE OF COGNITIVE FUNCTION AND BELIEF ABOUT MEDICATION

Nichapa Taibanguay

84 CO-MORBIDITIES IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TOCILIZUMAB Trang Tran Huyen

86 STUDY OF 31 PREGNANCIES DURING RHEUMATOID ARTHRITIS TREATMENT: TREATMENT COURSE, CONDITION OF NEWBORNS, AND PROBLEMS

Tomohiko Yoshida

87 SERUM LIPID ASSAY IN A LARGE COMMUNITY BASED RHEUMATOLOGY PRACTICE: INTERPRETATION AND CLINICAL USEFULNESS Kiran Adam89 INVESTIGATION OF RHEUMATOID ARTHRITIS PATIENTS WHO HAD RECEIVED LOWER EXTREMITY SURGERY Hiroshi Aonuma90 MODIFIABLE FACTORS ASSOCIATED WITH RESPONSE TO TREATMENT IN EARLY RHEUMATOID ARTHRITIS Zoe Brown91 IMPACT OF FOOT AND/OR ANKLE ARTHRITIS ON CLINICAL REMISSION Sung Hae Chang

92 WHAT AFFECTS JOINT DESTRUCTION OF LARGE JOINTS IN THE LOWER EXTREMITIES IN RHEUMATOID ARTHRITIS – A 4-YEAR LONGITUDINAL STUDY

Kohei Doi

93 USING TREAT-TO-TARGET STRATEGY BY DETERMINING PHYSICAL DISABILITY AND GLUCOCORTICOID REDUCTION STRONGLY INFLUENCE FUNCTIONAL REMISSION IN RHEUMATOID ARTHRITIS

Takafumi Hagiwara

94 IMPACT OF GLUCOCORTICOID USE ON FUNCTIONAL ABILITY IN PATIENTS WITH RHEUMATOID ARTHRITIS AFTER ACHIEVING CLINICAL REMISSION

Ryota Hara

95 QUALITY OF LIFE AND ITS DETERMINANTS IN ESTABLISHED RHEUMATOID ARTHRITIS Manjari Lahiri

96 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS Pongthorn Narongroeknawin

97 PREDICTIVE FACTOR FOR FOREFOOT DEFORMITY IN EARLY RHEUMATOID ARTHRITIS Yusuke Ozaki

98 AN INITIAL ATTEMPT OF USE OF A COMPOSITE DISEASE ACTIVITY SCORE (DAS) FOR EXTRA ARTICULAR MANIFESTATIONS IN RHEUMATOID ARTHRITIS (EAM-RA)

Prasanta Padhan

99 COMPARISON BETWEEN RAPID 3 AND CLINICAL DISEASE ACTIVITY INDEX (CDAI), AS A MEASURE OF DISEASE ACTIVITY IN INDIAN POPULATION WITH RHEUMATOID ARTHRITIS

Swetal Pandey

100 IMPORTANCE OF DRUG VERIFICATION AND ADHERENCE TO DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS Babar Salim

101 SUPERB MICROVASCULAR IMAGING COMPARED WITH CONVENTIONAL POWER DOPPLER IMAGING OF ACTIVE SYNOVITIS IN RHEUMATOID ARTHRITIS

Jung-Soo Song

102 PATIENT’S EXPECTATION AND SATISFACTION FOR JOINT SACRIFICING SURGERY ON RHEUMATOID FOREFOOT DEFORMITY Il-Hoon Sung103 AUTOMATED MULTIPARAMETER MICROSCOPY AND IMAGE ANALYSIS: NEXT GENERATION SYNOVIAL TISSUE HISTOLOGY Mihir Wechalekar

104 REAL-WORLD UTILIZATION AND OUTCOMES OF RHEUMATOID ARTHRITIS PATIENTS MANAGED WITH BIOLOGIC-DMARDS IN AN AUSTRALIAN TERTIARY HOSPITAL RHEUMATOLOGY OUTPATIENT CLINIC

Maryam Zia

105 AN INTERESTING CASE OF PULMONARY HYPERTENSION IN ELDERLY FEMALE Swetal Pandey

106 ECHOCARDIOGRAPHIC PROFILE IN SYSTEMIC SCLEROSIS PATIENTS IN RHEUMATOLOGY OUTPATIENT CLINIC CIPTO MANGUNKUSUMO GENERAL HOSPITAL JAKARTA

Faisal Parlindungan

107 SEEKING EVIDENCE OF CHROMOSOMAL DAMAGE IN SCLERODERMA Karen Patterson108 MUSCLE WEAKNESS WITH AN OVERLAP IN A 13 YEAR OLD MALE Babur Salim109 OUTCOME OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH SCLERODERMA: A 5 YEAR PROSPECTIVE COHORT STUDY Rohini Samant110 SUBCLINICAL ATHEROSCLEROSIS IN SYSTEMIC SCLEROSIS Yin Minn Soe

111 CLINICAL PRESENTATION AND INCIDENCE OF CARDIOPULMONARY COMPLICATIONS IN THAI EARLY SYSTEMIC SCLEROSIS (SSC) PATIENTS COMPARING BETWEEN DIFFERENCE AUTOANTIBODY PROFILES

Suparaporn Wangkaew

113 PREDICTORS OF DISEASE RELAPSE IN PREGNANCY AMONG MALAYSIAN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) Syahrul Sazliyana Shaharir




114 FACTORS ASSOCIATED WITH LOSS TO FOLLOW-UP AMONG SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS IN MYANMAR: A MIXED METHOD STUDY

Yin Minn Soe

115 OXIDATIVE STRESS IN SYSTEMIC LUPUS ERYTHEMATOSUS IS ASSOCIATED WITH HIGH DISEASE ACTIVITY AND DAMAGE: A SINGLE CENTRE STUDY FROM INDIA

Molly Thabah

116 OCULAR AND ORAL MANIFESTATIONS AMONG PATIENTS FROM THE SINGAPORE SJOGREN'S SYNDROME STUDY Bernard Thong

117 TO DETERMINE THE FREQUENCY OF VARIOUS TYPES OF INFECTIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN A TERTIARY CARE HOSPITAL

Tahira Perveen Umer

118 UNUSUAL CLINICAL PRESENTATION CAUSING DELAY IN DIAGNOSIS OF PRIMARY SJOGREN’S SYNDROME: OUR EXPERIENCE IN RHEUMATOLOGY CLINIC IN TERTIARY CARE HOSPITAL

Tahira Perveen Umer

119 HISTOPATHOLOGICAL FEATURES OF LUPUS NEPHRITIS OF SOUTH INDIAN ETHNIC TAMIL POPULATION: 10 YEAR SINGLE TERTIARY CENTER STUDY AT CHENNAI, INDIA

Krishnamurthy Venkataraman

120 A CASE REPORT: TREATMENT OF DIFFUSE ALVEOLAR HEMORRHAGE IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENT WITH INTRAVENOUS IMMUNOGLOBULIN

Ka Tong Wong

121 A MULTI-CENTRE RETROSPECTIVE COHORT STUDY ASSESSING INCIDENCE OF SERIOUS INFECTIONS IN LUPUS NEPHRITIS PATIENTS, COMPARED TO NON-RENAL SYSTEMIC LUPUS ERYTHEMATOSUS

Drew Yates

123 CLINICAL FEATURES AND RISK FACTORS OF PULMONARY EMBOLISM IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS Jiuliang Zhao

124 THE RISK FACTORS AND PROGNOSIS OF PRIMARY SJÖGREN'S SYNDROME-ASSOCIATED INTERSTITIAL LUNG DISEASE: A MULTI-CENTERED COHORT STUDY

Jiuliang Zhao

127 THE DIVERSITY OF IGH IMMUNE REPERTOIRE IN SLE ANALYZED BY HIGH THROUGHPUT SEQUENCING Chang-Youh Tsai

128 PRESUMED AUTOIMMUNE RETINOPATHY PRESENTING AS RETINITIS PIGMENTOSA IN A PATIENT WITH LOCALIZED DISCOID CUTANEOUS LUPUS ERYTHEMATOSUS

Eunice Victoria Co

129 IMPACT OF STRINGENT COMPLETE RENAL RESPONSE ON LONG-TERM RENAL OUTCOMES IN PROLIFERATIVE LUPUS NEPHRITIS Seokchan Hong

132 CONVENTIONAL IMMUNOMODULATORS ACHIEVE HIGH REMISSION IN SLE WITH NEPHRITIS - A ONE YEAR OBSERVATIONAL STUDY IN A TEACHING HOSPITAL

Yuva Vishalini Ravindran

133 SLEDAI-2K-RESPONDER INDEX-50 DEMONSTRATES EARLY RESPONSE IN A PHASE-2, RANDOMIZED PLACEBO-CONTROLLED STUDY OF USTEKINUMAB IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS

Shawn Rose

134 APIXABAN TREATMENT FAILURE PRESENTING AS RECURRENT THROMBOEMBOLISM IN ANTIPHOSPHOLIPID SYNDROME Georgia Smith

136 HYDROXYCHLOROQUINE INCREASES EFFEROCYTOSIS VIA MODULATING BOTH MERTK-GAS6/PROS AND INTEGRIN-TG2-MFGE8 PATHWAY

Gregory Tsay

137 THE ALTERATION OF REGULATORY T CELLS IN SYSTEMIC LUPUS ERYTHEMATOSUS WITH AND WITHOUT LUPUS NEPHRITIS Soamarat Vilaiyuk

139 ATYPICAL PRESENTATION: SPONTANEOUS SUBCAPSULAR RENAL HEMATOMA AND AUTOIMMUNE HEMOLYTIC ANEMIA IN MICROSCOPIC POLYANGITIS

Ing Soo Lau

140 REAL-WORLD EXPERIENCE OF POLYMYALGIA RHEUMATICA MANAGED IN A SINGLE TERTIARY CENTRE Jessica L Leung141 NMR BASED SERUM METABOLOMICS REVEALED DISTINCTIVE METABOLIC PATTERNS OF ANCA-ASSOCIATED VASCULITIS Ramnath Misra

143 ASSESSMENT AND PREDICTORS OF RESPONSE TO STEROID MONOTHERAPY IN PATIENTS OF TAKAYASU ARTERITIS IN BANGLADESHI POPULATION: AN OPEN-LABEL CLINICAL TRIAL

Farzana Shumy

144 SUCCESSFUL TREATMENT WITH CYCLOPHOSPHAMIDE IN A PATIENT WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS: A CASE REPORT

Mickaela Bianca Tanagon

145 THE EFFICACY AND SAFETY OF ADDITIONAL TOCILIZUMAB IN PATIENTS WITH POLYMYALGIA RHEUMATICA RESISTANT TO OR INTOLERANT OF CONVENTIONAL THERAPY

Akiko Ueno

146 THE INCIDENCE OF GRANULOMATOSIS WITH POLYANGIITIS AND TAKAYASU ARTERITIS IN TAIWAN Chien-Sheng Wu

147 A COMPARISON OF THE HEALTH ASSESSMENT QUESTIONNAIRE-DISABILITY INDEX AND MODIFIED HEALTH ASSESSMENT QUESTIONNAIRE TO ASSESS PHYSICAL FUNCTION IN POLYMYALGIA RHEUMATICA

Victor Yang

148 FACTORS PREDICTING PROGNOSIS OF GIANT CELL ARTERITIS: A RETROSPECTIVE STUDY OF CHINESE PATIENTS Yue Yin




APLAR-ARA 2019 abstracts are available in the International Journal of Rheumatic Diseases (IJRD) supplement.

USBVisit the Eli Lilly & Company booth #6 in the industry Exhibition Hall to collect a USB loaded with PDF copies of the IJRD abstract supplement and APLAR-ARA 2019 electronic handbook.

LILLY USB & ABSTRACT JOURNAL

DownloadAlternatively visit

http://bit.ly/APLAR19IJRDto download your copy of theIJRD supplement today!

1 2

#APLAR19 APLAR-ARA 2019 HANDBOOK 31

Proud sponsor of the congress abstract USB

Back to contents

INDUSTRY EXHIBITION

1 2

5 64

8

151617

9

Poster Gallery

Social Media Hub

Tour Desk

14

Lounge

18 19 20 21 22 23

12

13

11Native animals

24 25 26 27

7

3

Exhibitor Booth

Pfizer 1

Novartis 2

Celltrion 3

Roche 4

AbbVie 5

Eli Lilly 6

Amgen Australia 7

Janssen 8

UCB 9

Cytokine Signalling Forum 11

Thai Rheumatism Association 12

The Hong Kong Society of Rheumatology 13

Bristol-Myers Squibb 14

Gilead 15

APLAR 2020 Lounge 16

LG Chem 17

Japan College of Rheumatology 18

Australian Rheumatology Assocation 19

APLAR-AYR 20

Assocation of Women in Rheumatology 21

Link 22

SHL Group 23

Arthritis Australia 24

CreakyJoints Australia 25

Musculoskeletal Australia 26

Scleroderma Australia 27


https://aplar2019.com/sponsor/pfizer/

https://aplar2019.com/sponsor/novartis/

https://aplar2019.com/sponsor/celltrion/

https://aplar2019.com/sponsor/roche/

https://aplar2019.com/sponsor/abbvie/

https://aplar2019.com/sponsor/eli-lilly-company/

https://aplar2019.com/sponsor/amgen/

https://aplar2019.com/sponsor/janssen-a-division-of-johnson-johnson/

https://aplar2019.com/sponsor/ucb/

https://aplar2019.com/sponsor/bristol-myers-squibb/

https://aplar2019.com/exhibitor/gilead/

https://aplar2020.com/

https://aplar2019.com/sponsor/lg-chem/

https://aplar2019.com/sponsor/japan-college-of-rheumatology/

https://aplar2019.com/sponsor/ara/

https://aplar2019.com/about-aplar/

https://aplar2019.com/sponsor/association-of-women-in-rheumatology/

https://aplar2019.com/sponsor/link/

https://aplar2019.com/sponsor/shl/

SPONSOR PROFILES

Platinum Partners

Eli Lilly & CompanyLilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

To learn more about Lilly, please visit us at www.lilly.com and newsroom.lilly.com/social-channels.

NovartisNovartis is a global leader in immunology and dermatology. Our purpose is to reimagine medicine to improve people’s lives. We are transforming the lives of people living with immunologic diseases, focusing on specialty dermatology, rheumatology, autoinflammatory, transplant, and specialty liver diseases where there remain high unmet medical needs.

Novartis has a long history locally having commenced operations through our Sandoz division in Australia in 1957. We believe we have a responsibility to continue to help address unmet needs in healthcare locally – and we are committed to continuing to deliver new medicines and devices to help improve the health and wellbeing of Australians and New Zealanders, and people around the world.

www.novartis.com.au

PfizerWorking Together for a Healthier World®

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines. Our diversified global health care portfolio includes human biologic and small molecule medicines and vaccines, as well as many of the world’s best-known consumer products.

For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

www.pfizer.com.au


http://www.lilly.com

http://newsroom.lilly.com/social-channels

http://www.novartis.com.au

http://www.pfizer.com.au

Gold Partners

AbbVieAbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience.

www.abbvie.com.au

JanssenAt Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Learn more at www.janssen.com/australia. Follow us at www.twitter.com/JanssenANZ. Janssen-Cilag Pty Ltd is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

www.janssen.com.au

Industry Program Sponsors

AmgenAmgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

www.amgen.com.au

Bristol-Myers SquibbBristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube and Facebook.

www.bms.com


http://www.abbvie.com.au

http://www.janssen.com.au

http://www.amgen.com.au

http://www.bms.com

CelltrionAdvanced Therapeutics within Everyone’s Reach

Celltrion Healthcare is a global biopharmaceutical company committed to delivering high-quality and affordable therapeutics for patients.

We believe that every patient deserves access to treatments they need. Based on this belief, Celltrion Healthcare has been steadfast in our mission to meet the needs of patients who previously had limited access to advanced therapeutics since our inception in 1999 by developing biosimilar products. As a result, our biosimilar products have been approved in over 80 countries and being prescribed in more than 60 countries.

Opening a new era of biologics, we endeavour to offer high-quality cost-effective solutions in breakthrough therapies and contribute to global health. We will continue to work to be the world's leading life science company through innovative biologics.

www.celltrionhealthcare.com

RocheRoche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system.

www.roche-australia.com

UCBAt UCB, we aspire to be the patient-preferred biotech leader. Everything we do starts with a simple question: ’How will this create value for people living with severe diseases?’

UCB’s patient value strategy aims to deliver, through a deep understanding of patient subpopulations, unique outcomes and the best patient experience to as many lives as possible within specific populations.

With more than 7500 people in approximately 40 countries, UCB generated revenue of EUR 4.6 billion in 2018. UCB is listed on Euronext Brussels (symbol: UCB)

www.ucb.com


http://www.celltrionhealthcare.com

http://www.roche-australia.com

http://www.ucb.com

ACKNOWLEDGEMENTS

Platinum Partners

Gold Partners

Industry Program Sponsors

Women in Rheumatology Supporter

Congress AppSponsor

Congress Abstract USB Sponsor

Supporters


#APLAR19

handbook · ian wicks australia heather wisbey australia peter wong australia daniel wright new...

Documents